Genome-wide Meta-analysis Unravels Novel Interactions between Magnesium Homeostasis and Metabolic Phenotypes

Citation for published version:

Digital Object Identifier (DOI):
10.1681/ASN.2017030267

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published In:
Journal of the American Society of Nephrology

Publisher Rights Statement:
This is the author's peer reviewed manuscript as accepted for publication.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Genome-wide Meta-analysis Unravels Novel Interactions between Magnesium Homeostasis and Metabolic Phenotypes

<table>
<thead>
<tr>
<th>Journal:</th>
<th>Journal of the American Society of Nephrology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID:</td>
<td>JASN-2017-03-0267.R2</td>
</tr>
<tr>
<td>Manuscript Type:</td>
<td>Original Article - Meta-analysis</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>16-Jul-2017</td>
</tr>
</tbody>
</table>
| Complete List of Authors:       | Corre, Tanguy; Lausanne University Hospital, Institute for Social and Preventive Medicine; Universite de Lausanne, Department of Computational Biology; Swiss Institute of Bioinformatics
Arjona, Francisco; Radboud university medical center, Physiology
Hayward, Caroline; Institute of Genetics and Molecular Medicine, Western General Hospital
Youhanna, Sonia; Zurich Center for Integrative Human Physiology, University of Zurich, Institute of Physiology
de Baaij, Jeroen; Radboud university medical center, Physiology
Belge, Hendrica; University of Zurich, Institute of Physiology
Nagele, Nadine; Institute of Physiology, University of Zurich,
Debaix, Huguette; University of Zurich, Institute of Physiology
Blanchard, Maxime; Radboud university medical center, Physiology
Traglia, Michela; Ospedale San Raffaele, Division of Genetics and cell Biology
Harris, Sarah; University of Edinburgh, Centre for Cognitive Ageing and Cognitive Epidemiology; University of Edinburgh Centre for Genomic and Experimental Medicine and MRC Institute of Genetics and Molecular Medicine, Medical Genetics Section
Ulivi, Sheila; irccs burlo garofolo, medical genetics
Ruedi, Rico; Universite de Lausanne, Department of Computational Biology; Swiss Institute of Bioinformatics
Lamparter, David; Universite de Lausanne, Department of Computational Biology; Swiss Institute of Bioinformatics
Macé, Aurélien; Lausanne University Hospital, Institute for Social and Preventive Medicine; Swiss Institute of Bioinformatics
Sala, Cinzia; Ospedale San Raffaele, Division of Genetics and cell Biology
Lenarduzzi, Stefania; irccs burlo garofolo, medical genetics
Ponte, Belen; University Hospital of Geneva, Nephrology;
Pruijm, Menno; University Hospital of Lausanne, Nephrology
Ackermann, Daniel; Inselspital, University Hospital and University of Bern, Nephrology, Hypertension and Clinical Pharmacology
Ehret, Georg; Geneva University Hospital, Cardiology, Department of Specialties of Internal Medicine
Baptista, Daniela; Geneva University Hospital, Cardiology, Department of Specialties of Internal Medicine

ScholarOne support: 888-503-1050
Keywords: zebrafish, Genetic determinants, Magnesium homeostasis, Metabolic syndrome, Gene-environment interaction, Tubular transport
Genome-wide Meta-analysis Unravels Novel Interactions between Magnesium Homeostasis and Metabolic Phenotypes

Tanguy Corre*,1,3, Francisco J. Arjona*,4, Caroline Hayward*,5, Sonia Youhanna6, Jeroen H.F. de Baaij4, Hendrica Belge6, Nadine Nägele6, Huguette Debaix6, Maxime G. Blanchard4, Michela Traglia7, Sarah E. Harris8,9, Sheila Ulivi10, Rico Rueedi2,3, David Lamparter2,3, Aurélien Macé1,3, Cinza Sala7, Stefania Lenarduzzi10, Belen Ponte11, Menno Pruijm12, Daniel Ackermann13, Georg Ehret14, Daniela Baptista14, Ozren Polasek15, Igor Rudan16, Toby Hurd5, Nicholas D. Hastie5, Veronique Vitart6, Gerard Waeger17, Zoltán Katalik1,3, Sven Bergmann2,3,18, Rosa Vargas-Pousso19,20, Martin Konrad21, Paolo Gasparini22,23, Ian J. Deary8,24, John M. Starr8,25, Daniela Tonio1, Peter Vollenweider17, Joost G.J. Hoenderop4, René J.M. Bindels8,4, Murielle Bochud6,1, and Olivier Devuyst8,6

1 Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland
2 Department of Computational Biology, University of Lausanne, Lausanne, Switzerland
3 Swiss Institute of Bioinformatics, Switzerland
4 Department of Physiology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands
5 Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK
6 Institute of Physiology, University of Zürich, Zürich, Switzerland
7 Division of Genetics and cell Biology, San Raffaele Scientific Institute, Milano, Italy
8 Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK
9 Medical Genetics Section, University of Edinburgh Centre for Genomic and Experimental Medicine and MRC Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, UK
10 Institute for Maternal and Child Health - IRCCS “Burlo Garofolo” – Trieste, Italy
11 Service of Nephrology, University Hospital of Geneva (HUG), Switzerland
12 Service of Nephrology, University Hospital of Lausanne (CHUV), Switzerland
13 University Clinic for Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Switzerland
14 Cardiology, Department of Specialties of Internal Medicine, University Hospital of Geneva (HUG), Switzerland
15 Faculty of Medicine, University of Split, Split, Croatia
16 Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, EH8 9AG, UK
17 Department of Medicine, Internal Medicine, Lausanne University Hospital, 1011 Lausanne, Switzerland

1
Department of Integrative Biomedical Sciences, University of Cape Town, Cape Town, South Africa
Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Département de Génétique, Paris, France
Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte, Paris, France
Department of General Pediatrics, University Hospital Münster, Münster, Germany
Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
Department of Experimental Genetics, Sidra, Doha, Qatar.
Department of Psychology, University of Edinburgh, Edinburgh, UK
Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, UK

* T.C., F.J.A. and C.H. have equally contributed to the study
# O.D., M.B. and R.J.M.B. have co-directed the study

Running Title: Genetic determinants of magnesium homeostasis and metabolism

Corresponding authors: Prof. Dr. Olivier Devuyst, E-mail: olivier.devuyst@uzh.ch; or Prof. Murielle Bochud, E-mail: murielle.bochud@chuv.ch.
ABSTRACT

Magnesium (Mg\(^{2+}\)) homeostasis is critical for metabolism. The genetic determinants of the renal handling of Mg\(^{2+}\), which is crucial for Mg\(^{2+}\) homeostasis, and their potential influence on metabolic traits in the general population are unknown. Plasma and urine parameters were obtained of 9,099 individuals from 7 cohorts for the first genome-wide meta-analysis of Mg\(^{2+}\) homeostasis. Two novel loci, TRPM6 (rs3824347, \(P = 4.4 \times 10^{-13}\)) and ARL15 (rs35929, \(P = 2.1 \times 10^{-11}\)), for urinary Mg\(^{2+}\) (uMg) were identified, accounting together for 2.3% of the variation in 24-h uMg excretion. In human kidney cells, ARL15 was shown to regulate TRPM6-mediated currents. In zebrafish, the expression of the highly conserved ARL15 orthologue, arl15b, was regulated by dietary Mg\(^{2+}\) and arl15b-knockdown resulted in renal Mg\(^{2+}\) wasting and metabolic disturbances. The association of uMg with fasting insulin and fat mass was modified by ARL15 rs35929 in a general population. The combined observational and experimental approach uncovers a novel gene-environment interaction linking Mg\(^{2+}\) deficiency to insulin resistance and obesity.
INTRODUCTION

Magnesium (Mg\(^{2+}\)) is an essential cation for multiple enzymatic reactions, including those involving DNA and protein synthesis and energy metabolism\(^1\). Abnormal Mg\(^{2+}\) levels in serum are associated with common diseases such as diabetes and metabolic disorders\(^2\). Interventional and longitudinal observational studies in humans show that high dietary Mg\(^{2+}\) protects against the risk of developing type 2 diabetes\(^3\)–\(^6\) and improves glycemic control in diabetic patients\(^7\) as well as in overweight non-diabetic subjects\(^8\)–\(^10\). In young adults, high Mg\(^{2+}\) intake is significantly associated with lower incidence of metabolic syndrome\(^11\). Furthermore, there is evidence linking Mg\(^{2+}\) intake to body weight regulation, with low intake potentially impairing lean body mass growth\(^12, 13\), whereas Mg\(^{2+}\) supplementation may increase lean body mass and decrease fat mass in overweight women\(^14\).

Plasma Mg\(^{2+}\) levels are closely regulated and remain constant throughout life, despite the fact that dietary Mg\(^{2+}\) intake and intestinal absorption decrease with age\(^15\). The control of Mg\(^{2+}\) balance is ensured by a tightly regulated reabsorption of Mg\(^{2+}\) in the distal tubular segments of the kidney. In particular, the Mg\(^{2+}\) filtered in the glomerulus is reabsorbed in the proximal tubule and thick ascending loop of Henle (TAL) via paracellular routes, while downstream, in the distal convoluted tubule (DCT), Mg\(^{2+}\) is efficiently reabsorbed through transcellular mechanisms involving the transient receptor potential cation channel, subfamily M, member 6 (TRPM6)\(^2\). The reabsorption of Mg\(^{2+}\) in the DCT determines the final urinary Mg\(^{2+}\) (uMg) excretion since no reabsorption of Mg\(^{2+}\) occurs in posterior segments. Subjects harboring inherited or acquired dysfunctions of the renal tubular handling of Mg\(^{2+}\) show inappropriate urinary loss of Mg\(^{2+}\) causing chronic hypomagnesemia and severe, multi-systemic manifestations\(^2, 16, 17\).

The genetic component of Mg\(^{2+}\) homeostasis is indicated by a significant heritability (15-39%) of serum Mg\(^{2+}\)\(^18\),\(^19\) and by rare monogenic disorders disturbing renal tubular...
transport of Mg\textsuperscript{2+} \textsuperscript{20-23}. Yet, most of the regulatory genes of renal Mg\textsuperscript{2+} channels and transporters remain unknown. A genome-wide association study (GWAS) on serum Mg\textsuperscript{2+} in European ancestry adults identified six loci, one of which included the gene encoding TRPM6 \textsuperscript{24}. Two more recent studies in children \textsuperscript{25} and in African-Americans \textsuperscript{26} did not reveal additional loci. However, changes in uMg excretion precede changes in circulating serum Mg\textsuperscript{2+} levels, being thus a more sensitive indicator of any disturbance in Mg\textsuperscript{2+} homeostasis \textsuperscript{27}. Furthermore, Mg\textsuperscript{2+} depletion can be found in individuals with apparently normal total serum Mg\textsuperscript{2+} levels \textsuperscript{28}, which underscores the limitations of total serum Mg\textsuperscript{2+} as a marker of Mg\textsuperscript{2+} status. Assessment of uMg in GWAS is therefore crucial to elucidate new genes involved in Mg\textsuperscript{2+} homeostasis. Furthermore, studying the association between the genetic determinants of uMg and metabolic phenotypes linked to disturbed Mg\textsuperscript{2+} balance (e.g. obesity and diabetes) may provide novel insights on links between Mg\textsuperscript{2+} and common diseases. Indeed, plasma triglycerides and glucose are major determinants of the Mg\textsuperscript{2+} balance in diabetic patients \textsuperscript{29}.

In order to shed light on the genetic factors and molecular mechanisms linking Mg\textsuperscript{2+} handling and metabolic disorders, we performed a meta-analysis of GWAS for the renal handling of Mg\textsuperscript{2+} by combining genetic isolates and population-based studies and investigating the biological relevance of the identified loci using cellular systems and model organisms. Given the known relationships of Mg\textsuperscript{2+} intake with metabolic disorders, we also explored whether the identified loci modified these relationships. These studies establish a novel biological control of renal Mg\textsuperscript{2+} handling, and a novel gene-environment interaction sustaining the link between Mg\textsuperscript{2+} homeostasis, insulin resistance and obesity.
RESULTS

Meta-analyses of GWAS for magnesium homeostasis

The initial discovery phase consisted of a GWAS (2.5 M markers) performed on the population-based CoLaus cohort (5,150 samples) testing for association with uMg-to-creatinine ratio. The analysis revealed a single genome wide significant signal at rs3824347 ($P = 3.6 \times 10^{-8}$), corresponding to the TRPM6 locus on chromosome 9, and six suggestive loci with $P$ values below $10^{-5}$ (Suppl. Fig. 1). These association results were combined with the genome-wide association scans from six additional European cohorts (LBC1936, CROATIA-Split, CROATIA-Vis, Carlantino, CROATIA-Korcula, and Val Borbera) into a single meta-analysis (9,099 samples). As shown on the Manhattan plot (Fig. 1a), two signals showed a $P$ value below $5 \times 10^{-8}$. The QQ plot showed no problematic inflation ($\lambda=1.014$, se=$3.16 \times 10^{-5}$) (Suppl. Fig. 2a). Both the forest plots (Fig. 1b) and the low I-square values (Table 1) indicated little heterogeneity across cohorts. No secondary signals were detected in the approximate conditional analysis using the lead single nucleotide polymorphisms (SNPs) as covariates in the regression (Suppl. Fig 2b and 2c). The lowest combined $P$ value ($4.4 \times 10^{-13}$) was observed for the SNP rs3824347 on chromosome 9, at a locus comprising five genes, TRPM6, C9orf40, C9orf41, NMRK1 and OSTF1 (Fig. 1c). The second strongest signal maps to chromosome 5 with a $P$ value of $2.1 \times 10^{-11}$ for the lead SNP rs35929 (Fig. 1d). This SNP and all other genome-wide significant SNPs at this locus lie in the first intron of the ADP ribosylation factor like GTPase 15 (ARL15) gene. None of the two signals showed significant association with urinary creatinine.

Results from the versatile gene-based association study (VEGAS analysis) of uMg/creatinine ratio identified C9orf40, C9orf41 and TRPM6 as the only genes with a statistically significant result ($P < 2.8 \times 10^{-6}$), however these signals are overlapping with the single SNP association in the meta-analysis (rs3824347). None of the discovered SNPs tag
For Peer Review

copy number variations (CNVs). A pathway analysis has been performed using the Magenta algorithm, but no enrichment appeared to be significant after multiple testing correction. Sex-stratified analyses did not reveal additional genome-wide significant loci. No significant eQTL is referenced for rs35929 nor rs3824347 in the GTEx portal.

A meta-GWAS of serum Mg\(^{2+}\) levels replicated the previously published locus on chromosome 1\(^{24}\) containing among many others the gene MUC1 \((P = 4.45\times10^{-14})\) (Suppl. Table 1, Suppl. Fig. 3). Our meta-analysis on fractional excretion of Mg\(^{2+}\) (FEMg) yielded 12 suggestive loci with a \(P < 10^{-5}\) (Suppl. Fig. 4) but no genome-wide significant association (the sample size was reduced to cohorts having serum and urine from the same time point, therefore without LBC1936, Split and Vis; \(n = 7,976\)). The association of rs35929 \((P = 2.8\times10^{-4})\) and rs3824347 \((P = 1.4\times10^{-5})\) with FEMg were nominally, but not genome-wide, significant.

A genetic score including rs35929 and rs3824347 associates with uMg traits

Urinary Mg-to-creatinine ratio (Fig. 2a, CoLaus cohort), FEMg in spot urine (Fig. 2b, CoLaus cohort) and uMg excretion in 24-h urine (Fig. 2c, Swiss Kidney Project on Genes in Hypertension (SKIPOGH) cohort), but not serum Mg\(^{2+}\) (Fig. 2d, CoLaus), were strongly and linearly associated with an additive unweighted genetic risk score including rs35929-A (ARL15) and rs3824347-G (TRPM6) alleles. The genetic score explained 2.3% of 24-h uMg excretion in the SKIPOGH study and 1.0% of uMg-to-creatinine ratio in CoLaus.

ARL15 regulates TRPM6 channel activity

To validate the association between uMg excretion and ARL15 and TRPM6 variants, we first showed that the highest mRNA expression of Arl15 was in distal nephron segments including the TAL and DCT, the DCT being also strongly positive for Trpm6 (Fig. 3a). At protein
level, ARL15 is localized predominantly in the TAL and the DCT segments (Fig. 3b), which are enriched in Tamm-Horsfall (TH) protein and the Na$^+$-Cl$^-$-co-transporter (NCC) respectively. Importantly, TRPM6 is also distinctly localized in the DCT segment $^{31}$. The spatial correlation between TRPM6 and ARL15 expression in the DCT prompted us to postulate a functional interaction between these two proteins. In addition, functional protein association network analyses for ARL15 (Suppl. Fig. 5) showed that ARL15 interacts with key proteins for endocytic trafficking (RAB11 and ARFGEF families), a process that may increase the abundance and channel activity of TRPM6 in the plasma membrane.

To assess the potential effect of ARL15 on TRPM6 channel activity, human embryonic kidney 293 (HEK293) cells were transfected with wild type (WT) TRPM6 in parallel with a mock transfect, WT ARL15 or a dominant negative (T46N) ARL15 mutant. The T46N ARL15 mutant was predicted to be of dominant negative nature by comparative analysis with T27N ARF6, a dominant negative mutant affecting a protein (ARF6) that belongs to the same protein family as ARL15 $^{32}$. Patch clamp recordings showed characteristic slowly developing outwardly-rectifying currents in all conditions (Fig. 3c-f). A significant increase in TRPM6 channel activity was observed in the presence of WT ARL15, but not with the T46N ARL15 mutant (Fig. 3e). HEK293 cells express endogenous TRPM7 channels $^{33}$. Here, these currents were small (< 50 pA/pF) and were not significantly increased by expression of WT ARL15 (Fig. 3f).

**Physiological relevance of ARL15 in model organisms**

To support the important role of ARL15 in Mg$^{2+}$ homeostasis, we investigated the regulation of TRPM6 and ARL15 gene expression in mice upon exposure to variable Mg$^{2+}$ diets, known to affect the expression of critical genes in the mouse kidney and intestine $^{34}$, where Arl15 is expressed (Suppl. Fig. 6a). Metabolic profiling (Suppl. Tables 6-7) revealed a remarkable
adaptation after exposure to high and low Mg\textsuperscript{2+} diets, reflected by significant changes in the renal mRNA expression of \textit{Trpml6} and parvalbumin (\textit{Pvalb}), contrasting with the stable expression of \textit{Arl15} and other segmental markers of the TAL and DCT (Suppl. Fig. 6b). A similar effect was observed in the ileum and the caecum, also involved in Mg\textsuperscript{2+} handling\textsuperscript{2,34} (Suppl. Fig. 6c-d).

We further tested the biological relevance of \textit{ARL15} by using a zebrafish model, which shows tubular segmentation patterns that are equivalent to the mammalian kidney\textsuperscript{35}. Two distinct orthologs of mammalian \textit{ARL15} were identified in zebrafish: \textit{arl15a} and \textit{arl15b}, presenting 68\% and 83\% of AA identity respectively when aligned to the human counterpart (Suppl. Fig. 7a). Given the higher AA conservation of \textit{arl15b} compared to \textit{arl15a}, \textit{arl15b} was selected to study the function of its mammalian ortholog \textit{ARL15}. As mammalian \textit{ARL15}, \textit{arl15b} was ubiquitously expressed in all adult zebrafish tissues tested (Suppl. Fig. 7b). When adult zebrafish were fed different Mg\textsuperscript{2+} diets for 3 weeks, \textit{arl15b} expression patterns reflected compensatory mechanisms to cope with Mg\textsuperscript{2+} deficiency (kidney and gills) or Mg\textsuperscript{2+} surplus (gut) (Suppl. Fig. 7c-e).

A loss-of-function approach using morpholinos (MOs) against \textit{arl15b} in zebrafish larvae, where \textit{arl15b} is expressed in the pronephros (Suppl. Fig. 8), was used to relate \textit{ARL15} function to renal Mg\textsuperscript{2+} wasting. Since intestinal Mg\textsuperscript{2+} absorption does not take place during the time frame where the knockdown is applied, a change in zebrafish larvae Mg content reflects a change in the renal and/or skin (renal-like tissue\textsuperscript{36}) uptake of Mg\textsuperscript{2+}. Total Mg\textsuperscript{2+} content decreased consistently in \textit{arl15b} morphants compared with controls, indicating renal Mg\textsuperscript{2+} wasting since the pronephric kidney is the only extrusion route for Mg\textsuperscript{2+} (Fig. 4a-b). In parallel, cardiovascular impairments and morphological phenotypes characterized by a poorly metabolized yolk in comparison with controls, indicative of metabolic disturbances, were also observed (Fig. 4c-g). Co-injection of \textit{arl15b}-MO with human WT \textit{ARL15} cRNA
induced a rescue of all phenotypes observed, whereas co-injection with T46N ARL15 cRNA did not result in any rescue (Fig. 4h-k). These rescue experiments demonstrated the specificity of the renal Mg\(^{2+}\) wasting and metabolic defects associated to dysfunctional ARL15.

**Genetic background influences the link between uMg and metabolism phenotypes**

The functional relevance of ARL15 for Mg\(^{2+}\) homeostasis, as demonstrated in this study, in combination with the association between ARL15 and obesity and insulin biology\(^ {37}\) urged us to investigate a possible link between genetic background, renal Mg\(^{2+}\) handling and metabolic traits in general population cohorts.

Urinary Mg-to-creatinine ratio was associated positively with circulating fasting adiponectin ($P < 0.001$) and glucose levels ($P = 0.001$) as well as the presence of type 2 diabetes ($P = 0.03$), and negatively with body mass index (BMI) ($P = 0.001$), fasting triglycerides ($P = 0.012$), fasting insulin ($P = 0.03$), homocysteine ($P < 0.001$) and γ-glutamyl transeptidase (GGT) ($P < 0.001$), independently of serum Mg\(^{2+}\), in CoLaus (the largest cohort available). In CoLaus, the positive associations with adiponectin and fasting glucose, as well as the negative associations with BMI, GGT and homocysteine, remained significant ($P < 0.05$) upon adjustment for all the other metabolic phenotypes. In SKIPOGH, 24-h uMg excretion was negatively associated with fasting serum insulin ($P < 0.001$), even after adjustment for the all other metabolic covariates ($P = 0.003$). The negative associations of 24-h uMg excretion with fasting triglycerides or glucose disappeared upon adjustment for fasting insulin; we found no association of 24-h uMg excretion with BMI nor with fat mass ($P > 0.40$).

In CoLaus, the negative association of the ARL15 rs35929 variant with uMg excretion was stronger in overweight people ($P = 0.005$ for interaction between BMI and rs35929 for
their effect on uMg concentration in spot urine), in people with high fat mass ($P$ interaction = 0.024) (Fig. 5a), and in people with high fasting insulin levels ($P$ interaction = 0.012) (Fig. 5b), highlighting a SNP-by-environment interaction. In SKIPOGH, the negative association of daytime uMg excretion with fasting insulin was stronger in carriers of the $ARL15$ rs35929 A allele ($P$ interaction = 0.035), which is consistent with results in CoLaus in that rs35929 appears to modify the association between uMG excretion and fasting insulin. The corresponding $P$ values for interaction were 0.140 and 0.143 when replacing fasting insulin by BMI or fat mass, respectively.
DISCUSSION

In this multi-step study (Fig. 6), we conducted the first genome-wide meta-analysis for uMg levels using data from seven population-based studies of European descent. We identified two genome-wide significant loci associated with uMg-to-creatinine ratio: i) rs3824347 located on chromosome 9, near the TRPM6 gene coding for a Mg\(^{2+}\) channel; ii) rs35929 located on chromosome 5, an intronic variant of the ARL15 gene known for its association with adiponectin\(^{38}\) and lipid levels\(^{39,40}\), type 2 diabetes\(^{40}\), fasting insulin levels\(^{41}\) and coronary heart disease\(^{38}\), but without a prior physiological link to Mg\(^{2+}\) homeostasis. Using a multi-level approach, we provide robust evidence that ARL15 influences renal Mg\(^{2+}\) reabsorption through regulation of the Mg\(^{2+}\) channel TRPM6. An additive genetic score including the rs35929 A (ARL15) and rs3824347 G (TRPM6) alleles is strongly associated with 24-h uMg\(^{2+}\) excretion, a physiological test of Mg\(^{2+}\) status, which integrates both intestinal absorption and renal wasting\(^{42}\). In addition, the association of ARL15 rs35929 with uMg levels is modified by the metabolic status, and the association of uMg excretion with metabolic phenotypes is modified by ARL15 rs35929 in the general adult population.

Altogether, these findings suggest a gene-diet interaction relating Mg\(^{2+}\) homeostasis to metabolic disorders in the general population. If replicated in independent populations, the observed genetic effect sizes are sufficiently large to be of clinical and public health relevance.

In contrast to TRPM6, little is known about the function of the ARL15 gene, except its association with adiponectin and lipid levels, type 2 diabetes and higher fasting insulin levels in humans\(^{38-40,43}\). We found that ARL15 is highly expressed in the TAL and DCT, where Mg\(^{2+}\) reabsorption is mostly regulated and where the main bulk of Mg\(^{2+}\) is reabsorbed. Particularly, we show that ARL15 is enriched along with the well-characterized Mg\(^{2+}\) channel TRPM6 in the DCT, and that ARL15 increases TRPM6-mediated currents in renal
epithelial cells. Since TRPM6 is the gatekeeper in transepithelial Mg\textsuperscript{2+} transport, its regulation by ARL15 supports a key role of the latter in the transepithelial Mg\textsuperscript{2+} transport in the distal part of the nephron. ARL15 is structurally similar to Ras-related GTP-binding proteins, which regulate intracellular vesicle trafficking\textsuperscript{44}. It interacts with proteins of the RAB11 and ARFGEF families, which are also involved in endocytic traffic, suggesting that ARL15 regulates the trafficking of vesicular TRPM6 to the plasma membrane, thereby influencing Mg\textsuperscript{2+} reabsorption in the kidney. In this sense, our \textit{in vivo} data substantiated ARL15 as a key protein for the maintenance of Mg\textsuperscript{2+} homeostasis. This conclusion is supported by the high sensitivity of \textit{ARL15} expression to dietary Mg\textsuperscript{2+}, as demonstrated by the regulation of the highly conserved zebrafish ortholog of \textit{ARL15}, \textit{arl15b}, in the gut, kidney and gills of fish exposed to different Mg\textsuperscript{2+} diets – as it was already observed for the zebrafish ortholog of \textit{TRPM6}\textsuperscript{45}. Conversely, \textit{Arll5} expression in intestine and kidney remained unchanged in mice fed different Mg\textsuperscript{2+} diets. This discrepancy between the mouse and the zebrafish model might be due to that in zebrafish, and freshwater fish in general, active transcellular Mg\textsuperscript{2+} reabsorption is more prominent than in terrestrial vertebrates, as freshwater fish are hyperosmotic respect to the surrounding aquatic medium\textsuperscript{46,47}. Thus, the dietary Mg\textsuperscript{2+} challenge performed with mice in the present study is not sufficiently severe to evoke regulation of \textit{Arll5} expression.

The association of the \textit{ARL15} rs35929 variant with uMg excretion in the present GWAS predicted a physiological relevance of ARL15 in Mg\textsuperscript{2+} homeostasis. In agreement with these findings, knockdown experiments in the zebrafish recognized ARL15 as a relevant key protein that determines renal Mg\textsuperscript{2+} excretion. In agreement with previous GWAS linking \textit{ARL15} variants with risk of congestive heart disease\textsuperscript{38}, cardiovascular impairments, i.e. deficient tail blood circulation, was recognized in zebrafish \textit{arl15b} morphants. Furthermore, previous links between \textit{ARL15} and lipid metabolism\textsuperscript{37-39,43} were functionally supported in
zebrafish where arl15b morphants showed a poor mobilization of yolk metabolite reserves. In zebrafish larvae, the yolk serves mainly as a lipid store\textsuperscript{48,49}, therefore the deficiency in yolk absorption observed in arl15b morphants revealed poor lipid mobilization. The zebrafish arl15b morphants also accumulated fluid in the pericardial cavity and in the pronephros in the form of cysts showing kidney dysfunction. However, when lowering the intensity of the arl15b-knockdown (by using doses of 1 and 2 ng exon 4 skipping arl15b-MO/embryo), renal Mg\textsuperscript{2+} wasting was the only phenotype observed in the fish morphants. Therefore, the disturbances in Mg\textsuperscript{2+} balance observed in arl15b morphants are a primary effect of Arl15b dysfunction and not a secondary disturbance to the kidney/metabolic/cardiovascular phenotypes observed. The phenotype rescue experiments performed with normal or mutant versions of human ARL15 confirmed that renal Mg\textsuperscript{2+} wasting and metabolic defects were directly due to ARL15 knockdown. Altogether, the ARL15 functions unraveled in the present study illustrate an unprecedented case of shared pathophysiological genetics of renal Mg\textsuperscript{2+} wasting, cardiovascular disease and metabolic disorders, and demonstrate the pleiotropic nature of ARL15, that was inferred from the present and published GWAS. The importance of ARL15 is also supported by recent genetic evidence for its positive selection among adaptive loci identified in cattle\textsuperscript{50}. Thus far, no mutations in ARL15 have been associated with a monogenic disorder, including unidentified forms of renal Mg\textsuperscript{2+} wasting (Data not shown).

Could the metabolic traits linked to ARL15 variants be connected? By integrating intestinal absorption and renal wasting, uMg\textsuperscript{2+} excretion represents a physiological test of Mg\textsuperscript{2+} status, more suitable than total serum Mg\textsuperscript{2+} levels\textsuperscript{42}. Urinary Mg-to-creatinine ratio was associated with multiple metabolic phenotypes, independently of serum Mg\textsuperscript{2+}, in the population-based CoLaus study, providing novel insights into the metabolic consequences of Mg\textsuperscript{2+} deficiencies. Our results are in line with longitudinal studies in humans suggesting that
self-reported dietary Mg\(^{2+}\) intake may protect against type 2 diabetes, insulin resistance \(^{51}\) and metabolic syndrome \(^{52}\). Growing experimental evidence in favor of a beneficial role of Mg\(^{2+}\) intake on type 2 diabetes is accumulating in humans. Mg\(^{2+}\) supplements were found to significantly improve glucose tolerance and insulin sensitivity in diabetic and non-diabetic people \(^{53}\). Whether such benefit would persist over years is currently unknown. The public health relevance of dietary Mg\(^{2+}\) intake is further underscored by an association with all-cause mortality and risk of cardiovascular disease \(^{51}\). The novelty of our results is that we benefit from an objective measure of Mg\(^{2+}\) intake, namely uMg excretion, which, unlike circulating Mg\(^{2+}\), was found to be associated with the risk of ischemic heart disease \(^{54}\).

In population-based studies, the association between uMg and metabolic phenotypes (i.e. BMI, fat mass, fasting insulin levels) tended to differ by ARL15 rs35929 variants. These results are in line with human studies showing that Mg\(^{2+}\) intake exerts more protective effects on type 2 diabetes in overweight compared to non-overweight people \(^{3}\). Such gene-diet interaction has already been observed for type 2 diabetes, for which the increased risk conferred by the rs7903146 TCF7L2 genotype was only observed in the absence of lifestyle intervention \(^{55}\). Therefore, the ARL15 gene may modulate the beneficial effect of Mg\(^{2+}\) intake on insulin resistance in humans, offering a novel paradigm in nutrigenetics. Furthermore, the beneficial effect of high Mg\(^{2+}\) intake on metabolic disorders, such as type 2 diabetes and obesity, may not be uniform across individuals.

In conclusion, the translational data described in this study (Fig. 6) offer novel insights for the understanding of Mg\(^{2+}\) homeostasis and its relation with metabolic phenotypes, and identify ARL15 as a key and central player for these processes.
CONCISE METHODS

Genome-wide meta-analyses

Seven European population-based cohorts with Caucasian ethnicity (CoLaus, CROATIA-Vis, CROATIA-Korcula, CROATIA-Split, Lothian Birth Cohort 1936, INGI-Val Borbera, INGI-Carlantino, described in the Supplementary Information) participated in the study, with a total of 9,099 individuals. A variety of electrolytes including Mg\(^{2+}\) as well as creatinine, were measured in both urine and serum (methods and mean values described in the Supplementary Information).

All cohorts were whole genome genotyped before imputation using HapMap CEU panel as reference (Supplementary Information). Serum Mg\(^{2+}\) measurements and FEMg were subjected to quantile-quantile normalization in order to reach normality prior to performing linear regression. Urinary Mg\(^{2+}\) measurements expressed in mg/dl were first standardized to urinary creatinine, then corrected for age, sex and study specific covariates (such as ancestry principal components, study center…) before undergoing a quantile-quantile normalization. The approximately 2.5M SNPs passing quality control checks were subjected to a linear regression of the residuals for each phenotype, and association summary statistics were collected.

Even though quantile-quantile plots of the individual GWAS showed minimal inflation, ruling out the presence of population substructure, a genomic-control (GC) correction based on the lambda factor was applied to the association \(P\) values. Subsequently, a meta-analysis was conducted using the inverse variant weighting method implemented in METAL \(^{56}\). A new GC correction was applied to combined statistics.
SKIPOGH cohort

SKIPOGH is a population-based family-based multicentric study focusing on blood pressure regulation and renal function. Each participant collected 24-h urine. The study was approved by the institutional ethical committees of each participating university hospital and participants signed written informed consent.

VEGAS analysis

The SNP association $P$ values from the meta-analysis of uMg were analysed using VEGAS, a program for performing gene-based tests for association using the summary statistics from genetic association studies. VEGAS assigns SNPs to genes and combines their association $P$ values into a gene-based test statistic. Permutations are used to calculate the null distribution of the test statistic for each gene in order to derive an empirical gene-wise $P$ value. The gene-based approach also reduces the multiple-testing problem of GWAS by only considering statistical tests for 17,787 genes giving a Bonferroni-corrected threshold of $P < 2.8E^{-6}$.

Pathway analysis

We used Magenta to check enrichment for pathways in either the BIOCARTA KEGG REACTOME databases which were contained in the msigdb version 4.0 (http://www.broadinstitute.org/gsea/msigdb/collections.jsp#C2).

Metabolome analysis

Nuclear magnetic resonance spectroscopy data obtained from urine samples was binned and normalized to produce metabolome features. These features were then associated with the
SNPs of interest, including relevant covariates among standard covariates (age, sex, genotype principal components) and lifestyle factors (smoking, caffeine use, dietary intake, etc.).

**CNV analysis**

In house datasets have been used to call CNVs and to check their correlation with the SNPs of interest. The CNVs call has been done using pennCNV software. A SNP by sample matrix with the copy number status has been created. Then the square correlation (Pearson’s correlation) between value of each SNP of interest and the SNPs copy number status in a +/- 100 kb region has been calculated. For the SNPs of interest for which no correspondence has been found in the datasets, they have been replaced by the closest SNPs in high linkage disequilibrium (LD) and present in the datasets. LD between the SNPs of interest and a list of SNPs tagging CNVs from the Genetic Investigation of ANthropometric Traits (GIANT) consortium has also been calculated. The SNPs from the GIANT list are in LD higher than 0.8 with their corresponding CNV.

**Laboratory measurements**

Electrolytes, haematology parameters and glycaemia were dosed in the biochemical platform of the University of Zürich using standard clinical laboratory methods. Creatinine was measured using Jaffé kinetic compensated method (Roche Diagnostics, Switzerland, intra-assay variability 0.7-2.9%). The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula was used to calculate the estimated glomerular filtration rate (eGFR). In CoLaus, urinary uromodulin, creatinine, electrolytes and osmolality concentrations were measured in morning spot urine samples.

All urinary biochemical parameters were measured from samples stored at -80°C, using the same biochemical platform UniCel® DxC 800 Synchrom® Clinical System.
(Beckman Coulter, Nyon, Switzerland) at the University of Zürich. Appropriate controls and sets of calibration standards were used before running each sample batch. All cohorts were subjected to the same measurement protocol, in the same laboratory.

**Tissue distribution and localization of ARL15**

The tissue distribution of *ARL15* and of its highly conserved zebrafish ortholog *arl15b* was studied in adult mouse, adult zebrafish and zebrafish larvae, as described in the Supplementary Information. Segmental expression of ARL15 in the mouse (C57BL/6J) kidney was studied at both protein and mRNA level. Five-µm sections of fixed frozen kidney samples were co-stained for ARL15 and specific segment markers: breast cancer resistance protein (BCRP) for the proximal tubule (PT), TH for the TAL, NCC for the DCT, and aquaporin-2 (AQP2) for the collecting duct (CD). For mRNA expression, kidneys were dissected and minced, before isolation of well-characterized nephron segments. For more details of the immunohistochemistry, micro-dissection studies and mRNA analyses in the nephron segments, see the Supplementary Information.

**Functional studies in cells and animal models**

To study the regulation of TRPM6 channel activity by ARL15, human embryonic kidney 293 (HEK293) cells were transfected with 1 µg of human TRPM6 cDNA and 250 ng of empty vector (mock), human WT ARL15 or a human dominant negative (T46N) ARL15 mutant as negative control. Whole-cell patch clamp recordings were performed to determine the electrophysiological properties of the cells transfected with the constructs mentioned above (see details in the Supplementary Information).

The regulation of *ARL15* gene expression by dietary Mg$^{2+}$ was studied in C57BL/6J mice and Tupfel long-fin zebrafish (details in the Supplementary Information). These studies
were followed by a loss-of-function approach in zebrafish larvae using two non-overlapping splice-site blocking morpholinos (MOs): 5'-AAACACTGAAAGACGGGACAAAGAC-3'
and 5'-GTTAAGCGAGTAGGTACCTCT-3' (Gene Tools, Philomath, OR, USA), designated as exon skipping 3 and 4 arl15b-MO respectively. These antisense oligonucleotides were used to knockdown the highly conserved ARL15 ortholog in the zebrafish, arl15b. Phenotype rescue experiments were performed by co-injecting arl15b-MOs with human ARL15 cRNA as previously described and detailed in the Supplementary Information. The use of two non-overlapping arl15b-MOs and the combination with rescue experiments with human ARL15 cRNA served to rule out potential off-target effects in our knockdown approach.

**Statistical analyses in experiments performed in cellular and animal models**

All results are depicted as mean ± standard error of the mean (SEM). Statistical analyses were conducted by one-way ANOVA followed by the Tukey’s multiple comparison post-test. When only two experimental groups were affected by the factor of variance, an unpaired Student's t-test was used. Statistical significance was set at \( P < 0.05 \).

**Metabolic factors associated with uMg excretion**

We used multiple linear regression to explore the association between square-root-transformed uMg-to-creatinine ratio in spot urine and several metabolic markers (i.e. fasting triglycerides, total cholesterol, HDL-cholesterol, glucose, insulin, homocysteine, adiponectin, GGT and BMI), taken one-at-a-time as the dependent variable, while adjusting for serum Mg\(^{2+}\) and other potential confounders in SKIPOGH and CoLaus cohorts. In SKIPOGH, we used multivariate linear mixed effect regression to explore the association of fasting insulin with 24-h uMg excretion, while adjusting for potential confounders. We used a conservative
P value (0.05/9=0.0056) threshold to consider the associations of urinary Mg with metabolic phenotypes as statistically significant.

**SNP-by-environment interaction on uMg levels**

We explored the role of metabolic phenotypes on the association of ARL15 rs35929 with uMg levels in spot urine among CoLaus participants. We conducted multiple linear regression to explore the modifying effect of BMI, fat mass and fasting insulin levels on the association of the ARL15 rs35929 with square-root transformed uMg concentration, while including age, sex, height, lean mass, CKD-EPI, urinary creatinine (square-root), serum Mg^{2+}, serum and urine Ca^{2+} (square-root) and menopausal status. The P values for interaction were not corrected for multiple testing, as we tested a single global hypothesis (“does the association between rs35929 and urinary Mg differ by metabolic status?”) guided by prior knowledge.

**Note:** The datasets and summary statistics are available in the IUMSP Research Data Repository, under the link https://data.iump.ch/index.php/catalog/6.

ID Number: CHE-GWAS-V01. Created on July 12, 2017.
ACKNOWLEDGEMENTS

We thank Dr. Sjoerd Verkaart, Anke Hoefnagels and Sami G. Mohammed for their excellent technical support during the performance of the functional analyses and acknowledge Drs. Erwin van Wijk and Gert Flik for providing the facilities for zebrafish experimentation.

FUNDING

This work was supported by the Long-Term Fellowship from the European Renal Association - European Dialysis and Transplant Association (ERA LTF 175-2014) and the Impulsion Grant from the ERA-EDTA Working Group on Inherited Kidney Disorders (WGIKD) to FJA; and by the grant from the Netherlands Organization for Scientific Research (NWO VICI 016.130.668) to JGJH. JHFdB is supported by the grant from NWO (Rubicon 825.14.021) and RJMB by the EURenOmics project from the European Union Seventh Framework Programme (FP7/2007–2013, agreement no 305608). ZK received financial support from the Leenaards Foundation, the Swiss National Science Foundation (31003A-143914) and SystemsX.ch (51RTP0_151019). MBO and TC are supported by the Swiss National Centre of Competence in Research Kidney Control of Homeostasis (NCCR Kidney.CH) program. OD is supported by grants from the European Community’s Seventh Framework Programme (305608 EURenOmics), the Swiss National Centre of Competence in Research Kidney Control of Homeostasis (NCCR Kidney.CH) program, the Swiss National Science Foundation (31003A_169850) and the Rare Disease Initiative Zurich (radiz), a clinical research priority program of the University of Zurich, Switzerland.

The SKIPOGH study is supported by a grant from the Swiss national science foundation (FN 33CM30-124087). The CoLaus study is supported by research grants from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, and the Swiss National Science Foundation (grants 33CSCO-122661, 33CS30-139468 and 33CS30-148401).
CROATIA-Korcula and CROATIA-Split studies were funded by grants from the Medical Research Council (UK), European Commission Framework 6 project EUROSPAN (Contract No. LSHG-CT-2006-018947) and Republic of Croatia Ministry of Science, Education and Sports research grants to I.R. (108-1080315-0302). We would like to acknowledge the invaluable contributions of the recruitment team in Korcula and Split, the administrative teams in Croatia and Edinburgh and the people of Korcula and Split. The SNP genotyping for the CROATIA-Korcula cohort was performed in Helmholtz Zentrum München, Neuherberg, Germany. The SNP genotyping for the CROATIA-Split cohort was performed by AROS Applied Biotechnology, Aarhus, Denmark. INGI-Carlantino: We thank Anna Morgan and Angela D’Eustacchio for technical support; the municipal administrators for their collaboration on the project and for logistic support; and all participants to this study. For the INGI-VALBORBERA study, the research was supported by funds from Compagnia di San Paolo, Torino, Italy; Fondazione Cariplo, Italy and Ministry of Health, Ricerca Finalizzata 2008 to DT. Phenotype collection in LBC1936 was supported by Age UK (The Disconnected Mind project). Genotyping was funded by the BBSRC (BB/F019394/1). The work was undertaken by the University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (MR/K026992/1). Funding from the BBSRC and Medical Research Council (MRC) is gratefully acknowledged. We thank the LBC1936 participants, the LBC1936 team for data collection and collation, and the staff at the Wellcome Trust Clinical Research Facility for bio-sample collection and genotyping.

**COMPETING FINANCIAL INTERESTS:** None.
REFERENCES


ScholarOne support: 888-503-1050


36

ScholarOne support: 888-503-1050


Table 1: Summary statistics for the meta-analysis of uMg-to-creatinine ratio.

<table>
<thead>
<tr>
<th>SNP</th>
<th>Effect allele</th>
<th>Other allele</th>
<th>Mean effect allele frequency</th>
<th>Effect size discovery (SE)</th>
<th>p-value discovery</th>
<th>Effect size replication (SE)</th>
<th>p-value replication</th>
<th>Effect size Combined analysis (SE)</th>
<th>p-value combined analysis</th>
<th>Direction of effects of individual cohorts</th>
<th>I^2</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs35929</td>
<td>a</td>
<td>g</td>
<td>0.21</td>
<td>-0.112 (-0.025)</td>
<td>5.57x10^-6</td>
<td>-0.135 (-0.027)</td>
<td>5.95x10^-7</td>
<td>-0.1227 (-0.183)</td>
<td>2.11x10^-11</td>
<td>-----+-</td>
<td>35.7</td>
</tr>
<tr>
<td>rs3824347</td>
<td>g</td>
<td>a</td>
<td>0.41</td>
<td>-0.109 (-0.02)</td>
<td>3.61x10^-8</td>
<td>-0.1125 (-0.024)</td>
<td>2.02x10^-6</td>
<td>-0.1103 (-0.152)</td>
<td>4.38x10^-13</td>
<td>++++++</td>
<td>7</td>
</tr>
</tbody>
</table>

The effect size sign for each individual cohort on the last but one column is represented by the sign – or +. The cohort displaying a “-” for rs32929 is LBC1936, having anyhow an effect close to 0. The last column shows the I^2 value, representing the heterogeneity across cohorts.
LEGENDS TO FIGURES

Figure 1. Genome-wide meta-analysis results for uMg-to-creatinin Urinary Mg-to-creatinine ratio.

(a) Manhattan plot showing -log10(P values) for all SNPs in the genome-wide meta-analysis for normalized uMg-to-creatinine ratio in Europeans (n = 9,099), ordered by chromosomal position. The values correspond to the association of normalized uMg-to-creatinine ratio, including age and sex as covariates in the model as well as study-specific covariates if needed. The gene closest to the SNP with the lowest P value is listed at each locus. Two loci reached genome-wide significance (P < 5×10^-8) at combined analysis (TRPM6, rs3824347 and ARL15, rs35929). (b) Forest plot for rs35929 (ARL15) and rs3824347 (TRPM6) showing effect sizes and 95% confidence intervals across studies as well as the summary meta-analysis results. (c) Regional association plot at the rs3824347 (TRPM6) locus. Regional association plot showing -log10 P values for the association of SNPs at the locus of interest ordered by their chromosomal position with normalized uMg-to-creatinine ratio. The -log10 P value for each SNP is colored according to the correlation of the corresponding SNP with the SNP showing the lowest P value (index SNP) within the locus using different colors for selected levels of linkage disequilibrium (r2). Correlation structures correspond to HapMap 2 CEU. The blue line represents the recombination according to the scale shown on the right-side Y axis. (d) Regional association plot at the rs35929 (ARL15) locus. See Panel b legend.

Figure 2. External population-based validation using 24-h urine data.

(a-d) Associations of uMg excretion and fractional excretion with an unweighted genetic risk score including rs35929 (ARL15 locus) and rs3824347 (TRPM6 locus). Data are geometric
means and whiskers are 95% confidence intervals for Mg-related phenotypes in the CoLaus (panels a,b,d) and SKIPOGH (panel e) studies. The X axes represent the unweighted genetic score generated from rs35929 (ARL15 locus) and rs3824347 (TRPM6 locus), using as effect allele the one associated with lower uMg-to-creatinine ratio, i.e. the A allele for rs35929 and the G allele for rs3824347. P values are from non-parametric trend tests across genetic score. The numbers in each genetic score category are listed in all panels. The Y axis represents uMg-to-creatinine ratio (mg/g) (a), FEMg (%) (b), uMg excretion (mg/24h) (c) and serum Mg\textsuperscript{2+} (mg/dl) (d).

**Figure 3. ARL15 localizes in renal DCT regulating TRPM6 channel activity.**

(a) Gene expression analyses of *Trpm6, Arl15, Podocin, Sglt2, Snat3, Nkcc2, Ncc* and *Aqp2* in micro-dissected mouse nephron segments showed co-expression of *Arl15* and *Trpm6* in DCT. (b) Double immunofluorescence staining of mouse kidney cortex sections for ARL15 (in green) and BCRP (red); TH (red); NCC (red); or AQP2 (red) as markers of the PT, TAL, DCT or CD respectively. (c) Typical current-voltage curves obtained from transfected HEK293 cells 200 s after break-in. Outwardly-rectifying currents are observed in response to a 500 ms voltage ramp (from -100 to +100 mV) applied 200 s after break-in. (d) The average time development of the current density measured at +80 mV is shown (n ≥ 10). The mock + ARL15 condition is not shown for clarity reasons. (e) WT ARL15 (red, WT, n = 47) but not the T46N ARL15 mutant (black, T46N, n = 18) increased the whole-cell current density of TRPM6. Asterisks indicate significant differences respect to the cells transfected with *TRPM6* only (blue, ‘-’, n = 44). One-way ANOVA followed by Tukey’s multiple comparisons post-test, P < 0.05. (f) Transfection of
HEK293 cells with WT ARL15 did not evoke a significant increase in whole-cell current density when compared with mock-transfected of cells (n ≥ 10, unpaired Student's t-test).

**Figure 4. Physiological relevance of ARL15 in kidney.**

(a-b) Knockdown of arl15b by 0.5-2 (a) and 2-8 (b) ng/embryo of the two arl15b-MOs used (exon skipping 3 and 4 arl15b-MOs) resulted in a dose-dependent decrease of the total Mg content of zebrafish arl15b morphants, reflecting renal Mg\(^{2+}\) wasting. The zero dose represents injection with control-MO (2 (a) and 8 (b) ng MO/embryo). (c) Morphological phenotypes distinguished in zebrafish larvae (5 days post-fertilization (dpf)) following treatment with arl15b-MO or control-MO. A complete description of each phenotype is detailed in the Supplementary Information. Metabolic defects (poor metabolization of the yolk) are indicated by arrows. (d-g) Distribution of morphological phenotypes in zebrafish larvae injected with 0.5-2 (d, f) and 2-8 (e, g) ng/embryo of exon skipping 3 (d, e), exon skipping 4 (f, g) arl15b-MO or control-MO (2 (d, f) and 8 (e, g) ng MO/embryo). (h-k) Rescue of renal Mg\(^{2+}\) wasting (h, j) and of metabolism defects (i, k) in morphant zebrafish by co-injection of exon skipping 3 arl15b-MO (0.5 ng MO/embryo, h-i) or exon skipping 4 arl15b-MO (8 ng MO/embryo, j-k) with cRNA encoding human WT ARL15 (50 pg cRNA/embryo). Co-injection with cRNA encoding human T46N ARL15 mutant (50 pg cRNA/embryo) did not rescue renal Mg\(^{2+}\) wasting or the defects in metabolism. (d-g, i, k) Numbers on top of the bars indicate the number of animals in each experiment. (a-b, h, j) Data are presented as mean ± SEM (n = 10, except for b, where n = 6-10). (a-b, h, j) Asterisks indicate significant differences respect to the control condition (One-way ANOVA followed by Tukey’s multiple comparisons post-test, P < 0.05).
Figure 5. Effect modification of metabolic phenotypes on the association of uMg with the ARL15 locus.

(a) Effect modification of fat mass on the association of uMg concentration with rs35929 (ARL15) genotypes. Data represent adjusted square-root transformed uMg levels by rs35929 genotypes and fat mass strata in CoLaus. The model was adjusted for age, sex, height, lean mass, CKD-EPI, urinary creatinine (square-root), serum Mg\(^{2+}\), serum and urinary Ca\(^{2+}\) (square-root) and menopausal status. \(P\) interaction = 0.024. Fat mass strata are cut by sex-specific medians. \(n = 4,729\). (b) Effect modification of fasting insulin on the association of uMg levels with rs35929 (ARL15) genotypes. Data represent adjusted square-root transformed uMg levels by rs35929 genotypes and fasting insulin strata in CoLaus. The model was adjusted for age, sex, height, lean mass, CKD-EPI, urinary creatinine (square-root), serum Mg\(^{2+}\), serum and urinary Ca\(^{2+}\) (square-root) and menopausal status. \(P\) interaction = 0.012. Fat mass strata are cut by sex-specific medians (\(n = 4,729\)).

Figure 6. Multi-step approach used to investigate the genetic determinants of the renal handling of Mg\(^{2+}\) and their influence on metabolic traits in the general population.
Figure 1 - b

Effect sizes

rs35929 (ARL15)

rs3824347 (TRPM6)

COLAUS
CARLANTINO
KORCULA
LBC 1936
SPLIT
VAL BORBERA
VIS

Meta-analysis

Effect sizes

ScholarOne support: 888-503-1050
Figure 1 - d

Plotted SNPs

rs3824347

RORB → TRPM6 ← C9orf40 ← NMRK1
← C9orf41 → OSTF1

Position on chr9 (Mb)

0 2 4 6 8 10 12 14
- \log_{10}(p\text{-value})

0 20 40 60 80 100
Recombination rate (cM/Mb)

r^2

0.2
0.4
0.6
0.8

ScholarOne support: 888-503-1050
Figure 2

(a) Urine Mg/creatinine (mg/g)

(b) FEMg (%)

(c) Urine Mg (mg/24h)

(d) Serum Mg (mg/dl)
Figure 5

(a) Square-root urinary Mg

P trend = 0.017

P trend < 0.001

Low fat mass

n = 1282

n = 628

n = 78

High fat mass

n = 1327

n = 642

n = 71

(b) Square-root urinary Mg

P trend = 0.045

P trend < 0.001

Low fasting insulin

n = 1282

n = 628

n = 78

High fasting insulin

n = 1327

n = 642

n = 71

*GG, GA, AA*
**Discovery GWAS:** uMg-to-creat (CoLaus; N=5,150)
→ rs3824347 (chr 9, \textit{TRPM6})

**Meta-GWAS:** uMg-to-creat (CoLaus + LBC1936, LBC1936, CROATIA-Split, CROATIA-Vis, Carlantino, CROATIA-Korcula, Val Borbera; N=9,099)
→ rs3824347 (chr 9, \textit{TRPM6}) + rs35929 (chr 5, \textit{ARL15})

**Additive genetic risk score:** rs3824347 + rs35929
→ uMg-to-creat and FEMg (CoLaus); uMg 24h (SKIPOGH)

**Expression studies of ARL15 and TRPM6 in mouse kidney**
→ mRNA (RT-qPCR) and protein (immunofluorescence)

**Functional studies:** Influence of ARL15 on channel activity of TRPM6
→ Patch-clamp recordings on HEK293 cells transfected with ARL15 and TRPM6

**In vivo studies: Mouse** - Effects of magnesium diets (kidney, ileum, caecum)
→ Differential mRNA expression patterns (\textit{Arl15}, \textit{Trpm6}, other genes)

**In vivo studies: Zebrafish**
→ Identification of ARL15 orthologs
→ Expression of \textit{arl15b} in adult fish
→ Effect of magnesium diets on \textit{arl15b} expression patterns (kidneys, gills, gut – adult fish)
→ Loss-of-function and rescue (larvae): Magnesium balance and metabolic phenotypes

**Link genetic background (\textit{ARL15} rs35929) with renal magnesium handling and metabolic traits**
→ CoLaus: Association of uMg with metabolic traits
→ SKIPOGH: Association of 24h uMg with metabolic traits
→ CoLaus: Effect of body weight, BMI and fat mass on the association of rs35929 with uMg excretion
→ SKIPOGH: Effect of rs35929 on the association of uMg excretion with fasting insulin

ScholarOne support: 888-503-1050
Supplementary Information

Genome-wide Meta-analysis Unravels Novel Interactions between
Magnum Homeostasis and Metabolic Phenotypes

Table of contents:

Supplementary Methods
Supplementary Figures 1-10
Supplementary Tables 1-8
Supplementary References
SUPPLEMENTARY METHODS

GWAS Cohorts

**CoLaus** is a population-based cohort with baseline examination conducted between 2003 and 2006. It includes 6,184 individuals of European descent aged 35-75 years randomly selected from the registry of the city of Lausanne. The **CROATIA-Vis** study, Croatia, is a family-based, cross-sectional study in the isolated island of Vis that included 1,056 examinees aged 18-93. Blood samples were collected in 2003 and 2004. The **CROATIA-Korcula** study, Croatia, is a family-based, cross-sectional study in the isolated island of Korcula that included 965 examinees aged 18-95. Blood samples were collected in 2007. The **CROATIA-Split** study, Croatia, is population-based, cross-sectional study in the Dalmatian city of Split that so far includes 1,012 examinees aged 18-95. Blood samples were collected in 2009-2011. The **Lothian Birth Cohort 1936 (LBC1936)** consists of 1,091 relatively healthy older participants, most of whom took part in the Scottish Mental Survey of 1947 at the age of about 11 years. At a mean age of 69.5 years (SD 0.8) they were recruited to a study investigating influences on cognitive ageing. A second wave of cognitive and physical testing occurred at approximately 73 years of age at which time a urine sample was collected. The **INGI-Val Borbera** population is a collection of 1,785 genotyped samples (18-102 years) collected in the Val Borbera Valley, a geographically isolated valley located within the Appennine Mountains in Northwest Italy. The **INGI-Carlantino** study is a population-based, cross-sectional study in a village situated in the Southeastern part of the Apennines in a hilly area of the Puglia region. Main study characteristics are summarized in Suppl. Table 4, genotyping details on Suppl. Table 5.

Micro-dissection studies in mouse kidney

Well-characterized tubular segments were microdissected from mouse kidneys as described previously. Kidneys from male C57BL/6J mice were dissected and minced before incubation with 0.1% (w/v) type 2 collagenase solution that contained 100 μg/ml soybean trypsin inhibitor for 30 min at 37°C. After digestion, the supernatant was sieved through 250- and 80-μm nylon filters. Nephron fragments remained in the 80-μm sieve and were resuspended by flushing. Distinct segments [glomeruli (GLOM), proximal convoluted and straight tubules (PCT and PST respectively), thick ascending loop of Henle (TAL), distal convoluted tubule (DCT) and collecting duct (CD)] were isolated upon their morphologic features. Three collections were snap-frozen in liquid nitrogen and conserved at -80°C.
**Immunohistochemistry**

Nephron immunohistochemistry was performed as described previously. In short, co-staining for ARL15, breast cancer resistance protein (BCRP), Tamm-Horsfall protein (TH), thiazide sensitive Na⁺-Cl⁻ cotransporter (NCC) and aquaporin-2 (AQP2) was performed on 5-µm sections of fixed frozen mouse (C57BL/6J) kidney samples. The sections were incubated for 16 h at 4°C with the following primary antibodies: rabbit anti-ARL15 (1:100, Sigma Chemical Co., St Louis, USA), rat anti-BCRP (1:250), sheep anti-TH (1:750), rabbit anti-NCC (1:50) or rabbit anti-AQP2 (1:1000, kindly provided by Dr. Deen, Nijmegen, The Netherlands). For detection, kidney sections were incubated with Alexa Fluor-conjugated secondary antibodies. Images were taken with a Zeiss Axio Imager 1 microscope (Oberkochen, Germany) equipped with a HXP120 Kuller Codix fluorescence lamp and a Zeiss Axiocam MRm digital camera.

**Cell culture and transfection**

Human embryonic kidney 293 (HEK293) cells were grown at 37°C in DMEM (Biowhittaker Europe, Vervier, Belgium) supplemented with 10% (v/v) FCS (PAA Laboratories, Linz, Austria), non-essential amino acids (AAs), and 2 mM L-glutamine in a humidified 5% (v/v) CO₂ atmosphere.

Cells were seeded in 12-well plates and subsequently transfected with a total of 1.25 µg of cDNA (per well in a 12 wells plate) using Lipofectamine 2000 (Invitrogen, Breda, The Netherlands). HA-tagged human TRPM6 was in the pCINeo-IRES-GFP mammalian expression vector. A human ARL15 clone was obtained from Source BioScience (Berlin, Germany) and subcloned into the pCINeo-IRES-mCherry vector, used for transfections. The T46N mutation was inserted in the ARL15 construct using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer’s protocol. All constructs were verified by sequence analysis. Mock conditions were obtained by transfecting the empty pCINeo-IRES-mCherry vector. Approximately 36 h after transfection, cells were seeded on glass coverslips coated with 50 µg/ml fibronectin (Roche Diagnostics, Mannheim, Germany). Experiments were started 2 h after seeding the cells. Cells displaying both GFP and mCherry fluorescence were chosen for recording.

**Electrophysiology**

All experiments were performed at room temperature. Whole-cell recordings were undertaken and analyzed using an EPC-9 amplifier and the Patchmaster software (HEKA electronics,
Lambrecht, Germany). The sampling interval was set to 100 µs (10 kHz) with a low-pass filter set at 2.9 kHz. Pipettes were pulled from thin wall borosilicate glass (Harvard Apparatus, March-Hugstetten, Germany) and had resistance between 1 and 3 MΩ when filled with the pipette solution. Series resistance compensation was set to 75-95% in all experiments. Currents were elicited by a series of 500 ms voltage ramps (from -100 to +100 mV) applied every two seconds from a holding voltage of 0 mV. Current densities were obtained by normalizing the current amplitude to the cell capacitance.

The extracellular solution contained (in mM): 150 NaCl, 1 CaCl₂, 10 HEPES and pH adjusted to 7.4 using NaOH. The pipette solution was made of (in mM): 150 NaCl, 10 Na₂EDTA, 10 HEPES and pH adjusted to 7.2 using NaOH.

**Conservation of ARL15 proteins**

TBLASTN searches were performed on the mouse, cow and zebrafish genome database at NCBI (http://blast.ncbi.nlm.nih.gov/Blast.cgi) using the human ARL15 as query AA sequence. Sequences with a significant homology with human ARL15 were selected. Multiple sequence alignments were carried out using ClustalW (http://www.ebi.ac.uk/Tools/clustalw/) and the degree of AA conservation across species was discerned.

**Distribution of Arl15 gene expression and dietary Mg²⁺ challenge in mice**

To study the tissue distribution of Arl15 gene expression, three C57BL/6J mice were sacrificed; lung, bone, kidney, peritoneum, stomach, brain, heart, liver and muscle tissues were collected. The dietary Mg²⁺ challenge was performed on age- and gender-matched C57BL/6J wild type (WT) littermates. Mice were housed in a temperature- and light-controlled room with ad libitum access to standard pellet chow (SSNIFF Spezialdiäten, Soest, Germany) and deionized drinking water for 4 weeks until the start of the experiment. Three groups of mice were next fed a control diet (0.19% (w/w) Mg; n = 10), a Mg²⁺-deficient diet (0.0005% (w/w) Mg; n = 10), or a Mg²⁺-enriched diet (0.48% (w/w) Mg; n = 10) (SSNIFF Spezialdiäten, Soest, Germany) for 10 days. Mice were housed individually in metabolic cages overnight at baseline, day 5 and day 10 for urine collection (16 h sampling). Venous blood samples were obtained from the inferior vena cava during sacrifice at day 10, and kidneys and intestine (ileum and caecum) were harvested as previously described 13. All protocols were conducted in accordance with the National Research Council Guide for the Care and Use of Laboratory animals and were approved by the local Ethics Committee.
Distribution of arl15b gene expression and dietary Mg^{2+} challenge in zebrafish

Zebrafish from the Tupfel long-fin (TLF) strain were used for experimentation. For the study of the tissue distribution of the highly conserved ARL15 zebrafish ortholog (arl15b) in adult zebrafish tissues, 3 females and 3 males were dissected following anaesthesia (0.1% (v/v) 2-phenoxyethanol (Sigma Chemical Co., St Louis, USA)) and brain, ovary, gills, testis, heart, spleen, kidney, gut, operculum, scales and liver tissues were collected and stored at -80°C until analysis. In 5 days post-fertilization (dpf) larvae, animals were anaesthetised with tricaine/Tris pH 7.0 solution and pronephric tissue was isolated with fine-point needles under the microscope (Leica Microsystems Ltd). After removal of the yolk and swim bladder, the pronephros could be distinguished by the pigments that surround the pronephric tubules (Suppl. Fig. 8). Then, pronephric-enriched tissue was scratched and subsequently aspirated with a Pasteur pipette. Samples were constituted by 10 pronephros each, which were stored at -80°C until further analysis. Control genes were used to verify the purity of the pronephric tissue isolated: ncc, uniquely expressed in the pronephros, served as positive control; and ncc-like, whose gene expression is restricted to the skin, served as negative control.

To study the regulation of arl15b gene expression by the Mg^{2+} status in zebrafish ionoregulatory tissues (gills, kidney and gut), fish Mg^{2+} balance was challenged by different Mg^{2+} diets as previously reported. Briefly, 27 adult zebrafish were weighed and randomly divided into 3 groups of 9 animals each and kept in 3 separate 2-liter tanks. During 2 weeks (acclimation to control conditions), all fish were fed a Mg^{2+}-control diet (Hope Farms, Woerden, The Netherlands; 0.07% (w/w) Mg) at a daily ration of 2% (w/w) of the total body weight. After this period, for 2 groups, the control diet was replaced by a Mg^{2+}-deficient diet (Hope Farms; 0.01% (w/w) Mg) or a Mg^{2+}-enriched diet (Hope Farms; 0.7% (w/w) Mg). These 2 groups were kept under these feeding regimes for 3 weeks, while the remaining group (fed a Mg^{2+}-control diet) served as a control. At the end of this period, all groups were sampled. Sampling took place 24 h after the last feeding. Fish were anaesthetised in 0.1% (v/v) 2-phenoxyethanol (Sigma). After anaesthesia, death of animals was induced by spinal transaction and organs were collected, immediately frozen in liquid nitrogen and stored at -80°C until analysis. All animal procedures detailed here were performed in accordance with national and international legislation and were approved by the ethical review committee of the Radboud University Nijmegen.
Knockdown of the zebrafish ortholog of human ARL15 and rescue experiments

WT TLF zebrafish were bred and raised under standard conditions (28.5°C and 14 h of light: 10 h of dark cycle) in accordance with international and institutional guidelines. Zebrafish eggs were obtained from natural spawning. The following splice-site blocking morpholinos (MOs) were designed to knockdown arl15b expression: 5’-AAACACTGAAAGACGGGACAAAGAC-3’ and GTTAAGCGAGTATTAGGTACCTCT-3’ (Gene Tools, Philomath, OR, USA), designated as exon 3 and 4 skipping arl15b-MO respectively. A standard mismatch MO, directed against a human β-globin intron mutation, 5’-CCTCTACCTCAGTTACAATTATA-3’, was also used in the experiments to control for toxic effects of the MO molecule. MOs were diluted in deionized, sterile water supplemented with 0.5% (w/v) phenol red and injected in a volume of 1 nl into the yolk of one- to two-cell stage embryos using a Pneumatic PicoPump pv280 (World Precision Instruments, Sarasota, FL, USA). WT embryos (uninjected) were also included in the experiments to control for the effects of the injection procedure per se. To determine the most effective dose of the arl15b-MO, 0.5, 1 and 2 ng arl15b-MO; and 2, 4 and 8 ng arl15b-MO were injected in two sets of experiments. In these experiments, control embryos were injected with 2 or 8 ng of the standard mismatch control-MO (the highest dose for each set of experiments respectively). After injection, embryos from the same experimental condition were placed in 3 Petri dishes and cultured at 28.5°C in E3 embryo medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl₂, 0.33 mM MgSO₄), which was refreshed daily.

Morphological phenotypes characterizing kidney function and yolk metabolization were analyzed in larvae at 5 dpf. Larvae were classified into different classes of phenotypes on the basis of comparisons with stage-matched control embryos (injected with the control-MO) of the same clutch. In arl15b morphant larvae (5 dpf), 4 different phenotypes were distinguished: normal; mild, larvae with mild-moderate pericardial edema (indicative of kidney dysfunction) and metabolic defects (poor metabolization of the yolk); moderate, moderate pericardial edema accompanied by kidney cysts in approximately 75% of the cases, metabolic defects (poor metabolization of the yolk) and cardiovascular defects (poor blood circulation in the tail); severe, severe pericardial edema accompanied by kidney cysts in approximately 80% of the cases, metabolic defects (poor metabolization of the yolk) and cardiovascular defects (poor blood circulation or absence in the tail and severe bradychardia (heart beat rate below 100 beats per minute)). Representative images were obtained with a DFC450C camera (Leica Microsystems Ltd) after anaesthetising larvae with tricaine/Tris pH 7.0 solution.
For electrolyte measurements or RNA isolation, 7-10 zebrafish larvae were pooled as one sample. Samples were then snap frozen in liquid nitrogen and stored at -80°C in order to ensure euthanasia of animals.

*In vivo* cRNA rescue experiments were performed with human WT ARL15 and dominant negative mutant (T46N) ARL15 cRNAs. Constructs were sub-cloned into the pT7Ts expression vector, suitable for rescue experiments in zebrafish, and cRNAs were prepared using the mMESSAGE mMACHINE Kit (Ambion, Austin, TX, USA) according to the manufacturer's instructions. The cRNAs, in an amount of 50 pg, as based on previous studies, were (co)injected together with MOs as described above. Zebrafish larvae were phenotyped at 5 dpf.

**Electrolyte measurements in animal studies**

In mice, urinary creatinine and electrolytes as well as plasma urea and creatinine (enzymatic determination) were measured on a Synchron Unicel DxC 800 analyzer (Beckman Coulter, Brea, USA). In zebrafish, sample processing started by washing twice the samples with nanopure water in order to avoid contamination of remaining waterborne Mg$^{2+}$. Fish were then dried and digested as described previously. The total Mg content in each sample was determined with a colorimetric assay (Roche). Within-run precision and accuracy was controlled by means of an internal control Precinorm (CV = 0.8%). Furthermore, samples were normalized by protein content, which was determined with the Pierce BCA protein assay kit (Pierce Biotechnology, Rockford, IL, USA).

**RNA isolation and cDNA synthesis**

In mouse, total RNA was extracted from different tissues using the Aurum™ Total RNA Fatty and Fibrous Tissue Kit (Bio-Rad, Hercules, CA), following the manufacturer’s protocol. In zebrafish, RNA was isolated from zebrafish tissues and larvae using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions in which glycogen (Fermentas GmbH, St. Leon-Rot, Germany) was used in order to maximize the RNA recovery. This method allowed the isolation of more than 3 µg RNA per tissue or whole-larvae sample (n = 7-10 larvae/sample), and of more than 200 ng RNA per pronephric samples (10 pronephros/sample). In both, mouse and zebrafish RNA samples, one µg of RNA, or 200 ng in the case of pronephric samples, was subjected to DNase treatment to prevent genomic DNA contamination and subsequently used to perform the reverse transcriptase reaction.
Reverse transcription quantitative polymerase chain reaction (RT-qPCR)

Changes in target genes mRNA levels were determined by relative RT-qPCR following the MIQUE guidelines with a CFX96™ Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA) using iQ™ SYBR Green Supermix (Bio-Rad) detection of single PCR product accumulation. To study the effect of dietary Mg²⁺ on gene expression in mouse kidney, ileum and caecum, the geNorm algorithm was used with 5 reference genes to calculate the normalization factor (software geNorm version 3.4). The reference genes used encoded for β-actin (Actb), glyceraldehyde 3-phosphate dehydrogenase (Gapdh), peptidylprolyl isomerase A (Ppia), attachment region binding protein (Arbp) and hypoxanthine phosphoribosyltransferase 1 (Hprt1). In the rest of procedures with mice (tissue distribution and gene expression profile in different mouse nephron segments) and in the zebrafish studies, gene expression levels were normalized to the expression levels of the standard species-specific reference genes Gapdh (for mice) and elongation factor-1α (elf1α, for zebrafish). Here, relative mRNA expression was analysed using the Livak method (2^ΔΔCt). Primer sequences are shown in Suppl. Table 8.

Efficacy of the splice-site blocking arl15b-morpholinos. To determine the efficacy of the splice blocking induced by the exon 3 skipping arl15b-MO, cDNA from 5 dpf control (injected with 0.5 ng control-MO) and morphant (injected with 0.5 ng arl15b-MO) larvae was used for PCR analysis. The primers used were 5’- CGAGGTCACAGGGGTGTTTC-3’ as forward primer and 5’- GACGAAGCGCTGTCCAAAAC-3’ as reverse primer. Fragments thus obtained were extracted from a 1.5% agarose gel and Sanger-sequenced (Suppl. Fig. 9) to confirm the splice blocking induced.

In the case of the exon 4 skipping arl15b-MO, cDNA was generated from fish injected with 2 ng control or arl15b-MO. Primers used were 5’- CTGACGGGGTTCTGGGAAGAC-3’ as forward primer and 5’- ACCGTGCTTCCCTCTAGGAT-3’ as reverse primer. Given the absence of a spliced-arl15b transcript in 2-5 dpf fish (as a result of nonsense-mediated decay of arl15b mRNA by the exon 4 skipping arl15b-MO, Suppl. Fig. 10), the efficacy of the approach was further studied by RT-qPCR using specific primers that discriminate for the functional (non-spliced) arl15b transcript: the forward primer targets the exon 3-4 junction and the reverse primer targets exon 4 (Suppl. Table 8).
SUPPLEMENTARY FIGURES

Supplementary Figure 1. Manhattan plot from the GWAS on uMg-to-creatinine ratio for the CoLaus cohort.

Manhattan plot showing $-\log_{10}(P$ values) for all SNPs in the genome-wide association for normalized uMg-to-creatinine ratio in CoLaus (n=5,150), ordered by chromosomal position. The values correspond to the association of normalized uMg-to-creatinine ratio, including as covariates age, sex and the first principal components generated from all genotypes to take population structure into account. One locus ($TRPM6$) reached genome-wide significance ($P < 5\times10^{-8}$).
Supplementary Figure 2. QQ plot and conditional analyses for the uMg-to-creatinine ratio.

(a) QQ plot from the meta-analysis of uMg-to-creatinine ratio.
(b) Zoom plot showing the TRPM6 region’s associations to uMg-to-creatinine ratio after conditioning the analysis for rs3824347.
(c) Zoom plot showing the ARL15 region’s associations to uMg-to-creatinine ratio after conditioning the analysis for rs35929.
Supplementary Figure 3. Manhattan plot from the GWAS on serum Mg^{2+} levels for the meta-analysis.

(a) Manhattan plot showing all –log10(\(P\) values) for the combined analysis of the GWAS on serum Mg^{2+}, ordered by chromosome position. A locus on chromosome one reaches genome-wide significance. (b) Regional association plot of the region on chromosome one identified on the Manhattan plot on panel A. It shows a gene-rich locus, with no obvious candidate for being the gene involved.
Supplementary Figure 4. Manhattan plot from the meta-analysis of fractional excretion of Mg\(^{2+}\) (FEMg) GWASs.

Manhattan plot showing all –\(\log_{10}(P\) values\) for the combined analysis of the GWAS on FEMg, ordered by chromosome position. No signal reaches genome-wide significance.
Supplementary Figure 5. Functional protein association network analyses for ARL15.

ARL15 interacts with regulators of endocytic (RAB11FIP4, UBC) and vesicular (ARFGEF1) trafficking, factors involved in maintenance of cell polarity (ARFGEF1), factors influencing sodium handling (KNG1) and regulators of ubiquitination (UBC).

(http://string-db.org/cgi/network.pl?taskId=NPTdrqbgkFZS). Network nodes represent proteins, whereas different colored nodes refer to different proteins. Small nodes (MON2) refer to proteins of unknown 3D structure while large nodes represent proteins whose 3D structure is known or predicted (ARL15, KNG1, NUMBL, RAB11FIP3, RAB11FIP4, ARFGEF1, ARFGEF2, UBC, NUMB, FBXO8). Edges represent protein-protein associations: blue, interactions from curated databases (e.g. UBC-NUMB); magenta, experimentally determined interactions (e.g. ARL15-ARFGEF1, ARL15-ARFGEF2, ARL15-UBC, ARL15-MON2, ARL15-FBXO8); green, interactions derived from text mining (e.g. ARL15-RAB11FIP3, ARL15-RAB11FIP4, ARL15-NUMBL, ARL15-KNG1, ARL15-NUMB); purple, interactions deduced by protein homology (e.g. ARFGEF1-ARFGEF2).
Supplementary Figure 6. Tissue distribution of Arl15 gene expression in mouse tissues and regulation of gene expression by dietary Mg²⁺ in mouse tissues relevant for Mg²⁺ handling.

(a) Tissue distribution of Arl15 gene expression in mouse tissues. Relative gene expression in mouse tissues and organs was analysed using the Livak method ($2^{-\Delta\Delta Ct}$), where results are normalized against the reference genes Gapdh and expressed relative (%) to the gene expression in the kidney, chosen as calibrator. Data are presented as mean ± SEM (n = 3).

(b-d) Gene expression levels of Trpm6, parvalbumin (Pvalb), Arl15, the Na⁺-Cl⁻ cotransporter (Ncc), calbindin D-28k (Cabd28), the calcium-sensing receptor (Csr) and the Na⁺-K⁺-Cl⁻ cotransporter isoform 2 (Nkcc2) in mouse kidney (b); of Trpm6, Arl15, the zinc transporter 10 (Slc30a10) and the alpha subunit of the epithelial sodium channel (Alpha Enac) in mouse ileum (c); and Trpm6, Arl15, Slc30a10 and Alpha Enac in mouse caecum (d). Mice were fed a control diet (0.19% (w/w) Mg), a Mg²⁺-deficient diet (0.0005% (w/w) Mg), or a Mg²⁺-enriched diet (0.48% (w/w) Mg) for 10 days. Gene expression data were calculated using the geNorm algorithm and represent the mean fold difference (mean ± SEM, n = 10 for kidney and n = 5 for ileum and caecum) from the control group (mice on the control diet). *$P < 0.05$ compared with the control group.
Supplementary Figure 7. The zebrafish Arl15b protein is a highly conserved ortholog of human ARL15 being its gene expression is magnesiotropic in kidney, gills and gut.

a

<table>
<thead>
<tr>
<th>Species</th>
<th>Amino Acid Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human ARL5</td>
<td>NVDLLR1 EAFLYMDVC1FKCGGGPPARFEDYDLVCI1GLTGSKTSLLS8LCSESPE</td>
</tr>
<tr>
<td>Mouse ARL5</td>
<td>NVDLLR1 EAFLYMDVC1FKCGGGPPARFEDYDLVCI1GLTGSKTSLLS8LCSESPE</td>
</tr>
<tr>
<td>Cow ARL5</td>
<td>NVDLLR1 EAFLYMDVC1FKCGGGPPARFEDYDLVCI1GLTGSKTSLLS8LCSESPE</td>
</tr>
<tr>
<td>Zebrafish Arl15b</td>
<td>MVEHIQLSVA1CRIG1KNC1PKKCS1P1PE1D1Y1F1V1GL1L2P1S1D1S1E1A1</td>
</tr>
<tr>
<td>Zebrafish Arl15a</td>
<td>MVEHIQLSVA1CRIG1KNC1PKKCS1P1PE1D1Y1F1V1GL1L2P1S1D1S1E1A1</td>
</tr>
</tbody>
</table>

b

Zebradiish arl15b mRNA expression (% fold change)

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Expression ( % fold change )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain</td>
<td>120</td>
</tr>
<tr>
<td>Eye</td>
<td>60</td>
</tr>
<tr>
<td>Fin</td>
<td>0.001</td>
</tr>
<tr>
<td>Heart</td>
<td>0.07</td>
</tr>
<tr>
<td>Kidney</td>
<td>0.7</td>
</tr>
<tr>
<td>Operculum</td>
<td>0.001</td>
</tr>
<tr>
<td>Pectoral fins</td>
<td>0.07</td>
</tr>
<tr>
<td>Liver</td>
<td>0.7</td>
</tr>
</tbody>
</table>

Zebradiish kidney arl15b mRNA expression (% fold change)

Zebradiish gut arl15b mRNA expression (% fold change)

Magnesium content in the diets (w/w)
(a) Alignment of the human, mouse and cow ARL15 proteins (GenBank accession no. NP_061960, NP_766183 and NP_001014943 respectively) and zebrafish Arl15 paralogs: Arl15a and Arl15b (GenBank accession no. NP_001093503 and XP_001923547 respectively). Identical AA are boxed in black, conservative substitutions in gray. Sequence identity of zebrafish Arl15a with human, mouse and cow ARL15 is 68, 66 and 67% respectively. Zebrafish Arl15b displayed a strikingly high degree of AA conservation with its mammalian counterparts: 83, 81 and 79% with human, mouse and cow ARL15 respectively.

(b) Tissue distribution of arl15b gene expression in zebrafish tissues. Relative gene expression in mouse and zebrafish tissues and organs was analysed using the Livak method ($2^{-\Delta\Delta C_{t}}$), where results are normalized against the translational elf1a and expressed relative (%) to the gene expression in the brain, chosen as calibrator. Data are presented as mean ± SEM ( n = 6, except for the ovary and testis where n = 3). (c-e) Gene expression levels of arl15b in kidney (c), gills (d) and gut (e) of zebrafish on a Mg$^{2+}$-deficient diet (0.01% (w/w) Mg), Mg$^{2+}$-control diet (0.07% (w/w) Mg) and Mg$^{2+}$-enriched diet (0.7% (w/w) Mg) for 21 days. Data were calculated using the Livak method ($2^{\Delta\Delta C_{t}}$) and they represent the mean fold change (mean ± SEM, n = 8-9) from the control group (fish on the control diet). *P < 0.05 was considered statistically significant when compared with the control group.
Supplementary Figure 8. The *arl15b* gene is expressed in the pronephric kidney of zebrafish larvae.

(a) The pronephros of 5 dpf zebrafish larva after dissection for collection of pronephric-enriched tissue. Pronephric tubules can be distinguished by the black pigments that develop around the tubuli. (b) Gene expression of *arl15b* and the control genes *ncc* (uniquely expressed in the pronephros, as positive control) and *ncc-like* (distinctly expressed in the skin, as negative control) in the pronephros and total larvae. Relative gene expression was analysed using the Livak method ($2^{-\Delta\Delta C_t}$), where results are normalized against the reference gene *elf1a* and expressed relative (%) to the gene expression in total larvae. Data are presented as mean ± SEM (n = 3).
Supplementary Figure 9. Efficacy of the exon 3 skipping arl15b-MO used.

(a) Expected PCR products using forward (FW) and reverse (RV) primers located in exon 1 and 4 respectively on arl15b mRNA with normal splicing or altered splicing evoked by the arl15b-MO. (b) Gel electrophoresis image showing defects in the splicing process following injection of arl15b-MO (morphants, dose of 0.5 ng arl15b-MO/embryo) or control-MO (controls, dose of 0.5 ng control-MO/embryo). Bands showing correctly spliced arl15b mRNA and MO-spliced arl15b mRNA are shown. PCR was performed on cDNA prepared from larvae 5 days after injection. Shown on the left are the sizes (in bp) of the major bands of the DNA ladder. The expected amplicon size of the correctly spliced arl15b mRNA and the MO-spliced arl15b mRNA using FW and RV primers is of 411 bp and 351 bp respectively. (c) Chromatograms obtained from Sanger sequencing of the amplicons in the correctly spliced arl15b mRNA and the MO-spliced arl15b mRNA. The arl15b-MO evoked exon 3 skipping yielding a knockdown of Arl15b function. By skipping exon 3 with the arl15b-MO, the resulting protein lacks active domains such as the complete switch I region and part of the switch II region (switch regions are surface loops that undergo conformational changes upon GTP binding) and G3 box.
Supplementary Figure 10. Efficacy of the exon 4 skipping arl15b-MO used.

(a) Expected PCR products using forward (FW) and reverse (RV) primers located in exon 2 and 5 respectively on arl15b mRNA with normal splicing or altered splicing evoked by the arl15b-MO. (b) Gel electrophoresis image showing knockdown of arl15b gene expression following injection of arl15b-MO (morphants, dose of 2 ng arl15b-MO/embryo) or control-MO (controls, dose of 2 ng control-MO/embryo) in 2-5 dpf zebrafish larvae. Bands showing correctly spliced arl15b mRNA are shown, while bands showing MO-spliced arl15b mRNA could not be detected so that the exon 4 skipping arl15b-MO evoked nonsense-mediated decay of arl15b transcripts. Shown on the left are the sizes (in bp) of the major bands of the DNA ladder. The expected amplicon size of the correctly spliced arl15b mRNA and the MO-spliced arl15b mRNA (not detected) using FW and RV primers is of 413 bp and 204 bp respectively. (c-f) Characterization of the knockdown evoked by injection of 2 ng of exon 4 skipping arl15b-MO. Controls were injected with 2 ng of control-MO. C, total Mg content in
5 dpf morphant and control zebrafish larvae. Data are presented as mean ± SEM (n = 10). *P < 0.05 was considered statistically significant when compared with the control group. (d) Quantification of the knockdown evoked by the exon 4 skipping arl15b-MO by RT-qPCR using specific primers that discriminate for the correctly spliced (functional) arl15b mRNA. Data were calculated using the Livak method (2^ΔΔCt) and they represent the mean fold difference (mean ± SEM, n = 10) from the control group (fish injected with the control-MO). *P < 0.05 was considered statistically significant when compared with the control group. (e) Distribution of morphological phenotypes in the zebrafish larvae (5 dpf) used for the quantification of the arl15b knockdown by RT-qPCR. Numbers on top of the bars indicate the number of animals in each experimental condition. (f) Illustrative picture showing the characteristic phenotype (normal) evoked by knockdown of arl15b (2 ng/embryo of exon 4 skipping arl15b-MO).
SUPPLEMENTARY TABLES

Supplementary Table 1. Summary statistics for the genome-wide meta-analysis of serum Mg$^{2+}$ levels.

<table>
<thead>
<tr>
<th>Effect allele</th>
<th>Other allele</th>
<th>Mean effect allele frequency (SE)</th>
<th>Effect size discovery (SE)</th>
<th>$P$ value discovery</th>
<th>Effect size replica (SE)</th>
<th>$P$ value replica</th>
<th>Effect size combined analysis (SE)</th>
<th>$P$ value combined analysis</th>
<th>Direction of effects of individual cohorts</th>
<th>$I^2$</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs4460629</td>
<td>T</td>
<td>0.56</td>
<td>-0.144</td>
<td>4.89 x 10^{-13}</td>
<td>-0.100</td>
<td>1.15</td>
<td>-0.136</td>
<td>4.45 x 10^{-14}</td>
<td>--?</td>
<td>14.6</td>
</tr>
</tbody>
</table>

The effect size sign for each individual cohort on the last but one column is represented by the sign – or +. The cohort displaying a “?” is for the Carlantino cohort, not having data for rs4460629. The last column shows the $I^2$ value, representing the heterogeneity across cohorts.
Supplementary Table 2. Imputation status and quality for rs35929 and rs3824347.

<table>
<thead>
<tr>
<th>SNP</th>
<th>COLAUS</th>
<th>CARLANTINO</th>
<th>KORCULA</th>
<th>LBC1936</th>
<th>SPLIT</th>
<th>VAL</th>
<th>BORBERA</th>
<th>VIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs35929</td>
<td>I(0.95)</td>
<td>I(0.95)</td>
<td>I (1)</td>
<td>I(1)</td>
<td>I(1)</td>
<td>I(1)</td>
<td>I(1)</td>
<td>I(1)</td>
</tr>
<tr>
<td>rs3824347</td>
<td>I(0.97)</td>
<td>I(0.76)</td>
<td>I(0.95)</td>
<td>I(0.97)</td>
<td>I(0.98)</td>
<td>I(0.97)</td>
<td>I(0.98)</td>
<td>I(0.98)</td>
</tr>
</tbody>
</table>

Imputation status (G= genotyped, I=imputed) for both SNPs of interest in each cohort. Between brackets is the $r^2$ value representing imputation quality.
### Supplementary Table 3. Association of *ARL15* variants with metabolic phenotypes.

<table>
<thead>
<tr>
<th>Source</th>
<th>Trait</th>
<th>SNP</th>
<th>p-value of association in published GWAS</th>
<th>Chr</th>
<th>Position</th>
<th>Gene Region</th>
<th>Context</th>
<th>PubMed</th>
<th>reference allele</th>
<th>p-value for uMg/uCreat in Meta-analysis</th>
<th>Beta for uMg/uCreat in Meta-analysis</th>
<th>Standard error of Beta for uMg/uCreat in Meta-analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>dbGaP Body Weight</td>
<td>rs2042313</td>
<td>2.45x10-7</td>
<td>5</td>
<td>53212417</td>
<td>ARL15 Intron</td>
<td>17903300</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>dbGaP Body Weight</td>
<td>rs2042313</td>
<td>5.15x10-7</td>
<td>5</td>
<td>53212417</td>
<td>ARL15 Intron</td>
<td>17903300</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>NHGRI GWAS Catalog</td>
<td>Adiponectin</td>
<td>rs6450176</td>
<td>6.00x10-8</td>
<td>53298025</td>
<td>ARL15 Intron</td>
<td>22479202</td>
<td>a</td>
<td>0.59</td>
<td>0.0091</td>
<td>0.0169</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NHGRI GWAS Catalog</td>
<td>Cholesterol, HDL</td>
<td>rs6450176</td>
<td>5.00x10-8</td>
<td>53298025</td>
<td>ARL15 Intron</td>
<td>20686565</td>
<td>a</td>
<td>0.59</td>
<td>0.0091</td>
<td>0.0169</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NHGRI GWAS Catalog</td>
<td>Adiponectin</td>
<td>rs4311394</td>
<td>3.00x10-8</td>
<td>53300662</td>
<td>ARL15 Intron</td>
<td>20011104</td>
<td>a</td>
<td>0.63</td>
<td>-0.0079</td>
<td>0.0165</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dbGaP</td>
<td>Uric Acid</td>
<td>rs10513040</td>
<td>3.55x10-6</td>
<td>53502295</td>
<td>ARL15 Intron</td>
<td>17903292</td>
<td>a</td>
<td>0.052</td>
<td>-0.0663</td>
<td>0.0341</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Summary of previously associated SNPs in *ARL15* in published GWAS. The SNP associated with body weight is not present in our study. The 3 other SNPs are not significantly associated in the present uMg-to-creatinine meta-analysis, as shown in the last 3 columns.

## Supplementary Table 4. Study characteristics.

<table>
<thead>
<tr>
<th>Study</th>
<th>CoLaus</th>
<th>INGI-Val Borbera</th>
<th>INGI-Carlantino</th>
<th>CROATIA-Vis</th>
<th>CROATIA-Korcula</th>
<th>CROATIA-Split</th>
<th>LBC1936</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample size</td>
<td>5265</td>
<td>1541</td>
<td>281</td>
<td>195</td>
<td>889</td>
<td>489</td>
<td>660</td>
</tr>
<tr>
<td>Female % (N)</td>
<td>53%</td>
<td>56%</td>
<td>56.80%</td>
<td>58%</td>
<td>63.80%</td>
<td>56.50%</td>
<td>47.90%</td>
</tr>
<tr>
<td>Age, years mean (SD)</td>
<td>53.4 (10.7)</td>
<td>55 (18)</td>
<td>48 (19.7)</td>
<td>56.36 (15.5)</td>
<td>56.3 (13.9)</td>
<td>49.25 (14.7)</td>
<td>72.74 (0.75)</td>
</tr>
<tr>
<td>Serum Mg (mg/dl) mean (SD)</td>
<td>2.06 (0.166)</td>
<td>2.2 (0.3)</td>
<td>2.1 (0.2)</td>
<td>NA</td>
<td>2.04 (0.21)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Serum creatinine (mg/dl) mean (SD)</td>
<td>1.05 (0.24)</td>
<td>0.87 (0.25)</td>
<td>0.8 (0.2)</td>
<td>0.99 (0.32)</td>
<td>0.92 (0.18)</td>
<td>0.93 (0.15)</td>
<td>NA</td>
</tr>
<tr>
<td>Urine Mg (mg/dl) mean (SD)</td>
<td>6.9 (4.0)</td>
<td>8.4 (4.8)</td>
<td>8.1 (5)</td>
<td>5.93 (4.52)</td>
<td>7.6 (4)</td>
<td>8.76 (4.9)</td>
<td>8.70 (5.61)</td>
</tr>
<tr>
<td>Urine creatinine (mg/dl) mean (SD)</td>
<td>161.9 (81.4)</td>
<td>105.4 (59.1)</td>
<td>80.5 (42.1)</td>
<td>103.18 (65.8)</td>
<td>133.8 (63.8)</td>
<td>154.72 (72.98)</td>
<td>115.75 (62.20)</td>
</tr>
<tr>
<td>Urine Mg/creatinine (mg/gr) mean (SD)</td>
<td>46.51 (25.98)</td>
<td>88.6 (36.5)</td>
<td>104.6 (44.8)</td>
<td>62.55 (33.37)</td>
<td>63.7 (32.5)</td>
<td>60.6 (26.8)</td>
<td>82.03 (42.23)</td>
</tr>
<tr>
<td>FEMg mean (SD)</td>
<td>3.27 (1.65)</td>
<td>5.2 (2.5)</td>
<td>6.0 (2.6)</td>
<td>NA</td>
<td>2.55 (1.33)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>eGFR (mean, SD)</td>
<td>89.39 (20.03)</td>
<td>89.23 (23.28)</td>
<td>NA</td>
<td>89.41 (21.18)</td>
<td>87.72 (21.16)</td>
<td>94.92 (23.34)</td>
<td>NA</td>
</tr>
</tbody>
</table>
Supplementary Table 5. Study genotyping characteristics.

<table>
<thead>
<tr>
<th>Study</th>
<th>CoLaus</th>
<th>INGI-Val Borbera</th>
<th>INGI-Carlantino</th>
<th>CROATIA-Vis</th>
<th>CROATIA-Korcula</th>
<th>CROATIA-Split</th>
<th>LBC1936</th>
</tr>
</thead>
<tbody>
<tr>
<td>Array type</td>
<td>Affymetrix 500K</td>
<td>Illumina 370k</td>
<td>Illumina 370k</td>
<td>Illumina HumanHap300v1</td>
<td>Illumina HumanHap370CNV</td>
<td>Illumina HumanHap370CNV</td>
<td>Illumina 610</td>
</tr>
<tr>
<td>Genotype calling</td>
<td>BRLMM</td>
<td>BeadStudio analysis software</td>
<td>BeadStudio analysis software</td>
<td>Genome Studio</td>
<td>Genome Studio</td>
<td>Genome Studio</td>
<td>Genome studio</td>
</tr>
<tr>
<td>QC filters for genotyped SNPs used for imputation</td>
<td>pHWE&lt;1e-7, individual call rate &gt;90%; SNP call rate=70%; MAF=0.01</td>
<td>call rate &gt;= 90%; MAF &gt;= 1%; pHWE p &gt; 0.0001</td>
<td>call rate &gt;= 90%; MAF &gt;= 1%; pHWE p &gt; 0.0001</td>
<td>SNP Call rate&lt;0.98, MAF&lt;0.01, pHWE&lt;1e-6, Individual Call rate&lt;0.95</td>
<td>SNP Call rate&lt;0.98, MAF&lt;0.01, pHWE&lt;1e-6, Individual Call rate&lt;0.95</td>
<td>SNP Call rate&lt;0.98, MAF&lt;0.01, pHWE&lt;1e-6, Individual Call rate&lt;0.95</td>
<td>pHWE p &lt; 1x10-3 individual call rate &lt;95%; SNP call rate&lt;98%; MAF&lt;0.01</td>
</tr>
<tr>
<td>No of SNPs used for imputation</td>
<td>390'631</td>
<td>332'887</td>
<td>309'430</td>
<td>289'827</td>
<td>307'625</td>
<td>321'456</td>
<td>~500,000</td>
</tr>
<tr>
<td>Imputation</td>
<td>IMPUTE v0.2</td>
<td>MACH</td>
<td>MACH</td>
<td>MACH 1.0.16</td>
<td>MACH 1.0.16</td>
<td>MACH 1.0.16</td>
<td>MACH</td>
</tr>
<tr>
<td>Filtering of imputed genotypes</td>
<td>None</td>
<td>Rsq&lt;0.3</td>
<td>Rsq&lt;0.3</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>none</td>
</tr>
<tr>
<td>Data management and statistical</td>
<td>QUICKTEST</td>
<td>R, GenABEL, ProbABEL (mmasc function was used to R, GenABEL, ProbABEL (mmasc function</td>
<td>R, GenABEL, ProbABEL (mmasc function</td>
<td>R, GenABEL, ProbABEL (mmasc function</td>
<td>R, GenABEL, ProbABEL (mmasc function</td>
<td>R, GenABEL, ProbABEL (mmasc function</td>
<td>mach2qtl</td>
</tr>
<tr>
<td>Population stratification or Principal Components</td>
<td>analysis</td>
<td>account for relatedness</td>
<td>function was used to account for relatedness</td>
<td>was used to account for relatedness</td>
<td>was used to account for relatedness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>----------</td>
<td>-------------------------</td>
<td>---------------------------------------------</td>
<td>-----------------------------------</td>
<td>-----------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>We included the first 3 principal components as covariates</td>
<td>We included the first 3 principal components as covariates</td>
<td>We included the first 3 principal components as covariates</td>
<td>We included the first 3 principal components as covariates</td>
<td>We included the first 3 principal components as covariates</td>
<td>We included the first 4 principal components as covariates</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Supplementary Table 6. Urine (U) parameters in mice fed different Mg²⁺-containing diets.

<table>
<thead>
<tr>
<th></th>
<th>Control diet (n=10)</th>
<th>Mg²⁺ deficient diet (n=11)</th>
<th>Mg²⁺ excess diet (n=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>23.7 ± 0.4</td>
<td>23.9 ± 0.8</td>
<td>25.6 ± 0.4*</td>
</tr>
<tr>
<td>Diuresis (µl/16h)</td>
<td>1307 ± 162</td>
<td>1467 ± 244</td>
<td>1985 ± 285</td>
</tr>
<tr>
<td>Diuresis (µl/min.gBW)</td>
<td>0.058 ± 0.007</td>
<td>0.066 ± 0.012</td>
<td>0.080 ± 0.012</td>
</tr>
<tr>
<td>U Na⁺ (nmol/min)</td>
<td>164 ± 16</td>
<td>170 ± 19</td>
<td>177 ± 15</td>
</tr>
<tr>
<td>U K⁺ (nmol/min)</td>
<td>413 ± 40</td>
<td>479 ± 42</td>
<td>501 ± 46</td>
</tr>
<tr>
<td>U Cl⁻ (nmol/min)</td>
<td>229 ± 21</td>
<td>263 ± 29</td>
<td>265 ± 26</td>
</tr>
<tr>
<td>U Mg²⁺ (nmol/min)</td>
<td>586 ± 59</td>
<td>621 ± 54</td>
<td>656 ± 78</td>
</tr>
<tr>
<td><strong>Day 5</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>24.3 ± 0.5</td>
<td>24.3 ± 0.8</td>
<td>25.8 ± 0.5*</td>
</tr>
<tr>
<td>Diuresis (µl/16h)</td>
<td>1064 ± 49</td>
<td>1390 ± 168</td>
<td>1126 ± 132*</td>
</tr>
<tr>
<td>Diuresis (µl/min.gBW)</td>
<td>0.046 ± 0.002</td>
<td>0.060 ± 0.01</td>
<td>0.045 ± 0.005*</td>
</tr>
<tr>
<td>U Na⁺ (nmol/min)</td>
<td>156 ± 14</td>
<td>171 ± 20</td>
<td>123 ± 20</td>
</tr>
<tr>
<td>U K⁺ (nmol/min)</td>
<td>382 ± 36</td>
<td>393 ± 45</td>
<td>327 ± 52*</td>
</tr>
<tr>
<td>U Cl⁻ (nmol/min)</td>
<td>210 ± 20</td>
<td>239 ± 28</td>
<td>168 ± 30*</td>
</tr>
<tr>
<td>U Mg²⁺ (nmol/min)</td>
<td>478 ± 42</td>
<td>13 ± 3*</td>
<td>1269 ± 184*</td>
</tr>
<tr>
<td><strong>Day 10</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>24.1 ± 0.4</td>
<td>24.3 ± 0.9</td>
<td>25.9 ± 0.5*</td>
</tr>
<tr>
<td>Diuresis (µl/16h)</td>
<td>1516 ± 136</td>
<td>1447 ± 149</td>
<td>1334 ± 124*</td>
</tr>
<tr>
<td>Diuresis (µl/min.gBW)</td>
<td>0.066 ± 0.006</td>
<td>0.062 ± 0.005</td>
<td>0.053 ± 0.005*</td>
</tr>
<tr>
<td>U Na⁺ (nmol/min)</td>
<td>189 ± 16</td>
<td>176 ± 23</td>
<td>140 ± 18</td>
</tr>
<tr>
<td>U K⁺ (nmol/min)</td>
<td>532 ± 46</td>
<td>465 ± 43</td>
<td>409 ± 51</td>
</tr>
<tr>
<td>U Cl⁻ (nmol/min)</td>
<td>287 ± 26*</td>
<td>263 ± 33</td>
<td>195 ± 28*</td>
</tr>
<tr>
<td>U Mg²⁺ (nmol/min)</td>
<td>723 ± 49</td>
<td>8.1 ± 1.7*</td>
<td>1399 ± 149*</td>
</tr>
</tbody>
</table>

*P < 0.05 versus control diet; †P < 0.05 versus baseline; ‡P < 0.05 versus day 5
### Supplementary Table 7. Plasma (P) parameters in mice fed different Mg\(^{2+}\)-containing diets.

<table>
<thead>
<tr>
<th>Day 10</th>
<th>Control diet ( (n=10) )</th>
<th>Mg(^{2+}) deficient diet ( (n=11) )</th>
<th>Mg(^{2+}) excess diet ( (n=10) )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)</td>
<td>23.4 ± 0.5</td>
<td>23.3 ± 0.8</td>
<td>24.5 ± 0.6</td>
</tr>
<tr>
<td>P urea (mg/dl)</td>
<td>51.4 ± 1</td>
<td>64.7 ± 3.9*</td>
<td>52.0 ± 2.6*</td>
</tr>
<tr>
<td>P creatinine (mg/dl)</td>
<td>0.07 ± 0.01</td>
<td>0.07 ± 0.01</td>
<td>0.08 ± 0.01</td>
</tr>
<tr>
<td>P Na(^+) (mmol/l)</td>
<td>154 ± 1</td>
<td>157 ± 1*</td>
<td>152 ± 1*</td>
</tr>
<tr>
<td>P K(^+) (mmol/l)</td>
<td>4.0 ± 0.2</td>
<td>4.4 ± 0.1*</td>
<td>4.7 ± 0.2*</td>
</tr>
<tr>
<td>P Cl(^-) (mmol/l)</td>
<td>110 ± 1</td>
<td>111 ± 1</td>
<td>108 ± 1</td>
</tr>
<tr>
<td>P Ca(^{2+}) (mmol/l)</td>
<td>2.26 ± 0.03</td>
<td>2.06 ± 0.03*</td>
<td>2.29 ± 0.03*</td>
</tr>
<tr>
<td>P Mg(^{2+}) (mg/dl)</td>
<td>2.95 ± 0.10</td>
<td>1.08 ± 0.11*</td>
<td>3.13 ± 0.13*</td>
</tr>
</tbody>
</table>

*\( P < 0.05 \) versus control diet; †\( P < 0.05 \) versus Mg\(^{2+}\) deficient diet
Supplementary Table 8. Primer oligonucleotide sequences used in the present study during RT-qPCR measurements.

<table>
<thead>
<tr>
<th>Primer sequence 5’ → 3’</th>
<th>Species</th>
<th>Amplicon size (bp)</th>
<th>Efficiency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actb</td>
<td>Mouse</td>
<td>102</td>
<td>102</td>
</tr>
<tr>
<td>Forward TGCCCATCTATGAGGGCTAC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reverse CCCGTTCAAGCTGGATCTTC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arl15</td>
<td>Mouse</td>
<td>133</td>
<td>98</td>
</tr>
<tr>
<td>Forward TCATCAAGACAAGCCAGCAG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reverse GCTGTCCCTTCAGTGTCACA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gapdh</td>
<td>Mouse</td>
<td>176</td>
<td>104</td>
</tr>
<tr>
<td>Forward TGCACCACCAACTGCTTAGC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reverse GGATGCAGGGATGGGGGAGA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Podocin</td>
<td>Mouse</td>
<td>162</td>
<td>103</td>
</tr>
<tr>
<td>Forward GTCTAGCCATGTGTCAAA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reverse CCACTTTGATGCCCAAATA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pvalb</td>
<td>Mouse</td>
<td>136</td>
<td>97</td>
</tr>
<tr>
<td>Forward GACGCCATTTTCTGGAAT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reverse ATACCCCCACAGCCCTAAA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arbp</td>
<td>Mouse</td>
<td>150</td>
<td>99</td>
</tr>
<tr>
<td>Forward CTTCATGTGGAGACAGACA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reverse TTCTCCAGAGCTGGTTGTT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ncc</td>
<td>Mouse</td>
<td>148</td>
<td>101</td>
</tr>
<tr>
<td>Forward CATGGTCTCTTTGCAACT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gene</td>
<td>Forward Sequence</td>
<td>Reverse Sequence</td>
<td>Species</td>
</tr>
<tr>
<td>-----------</td>
<td>---------------------------------------</td>
<td>---------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Nkcc2</td>
<td>CCGTGCCCTACATAGGTGTT</td>
<td>GGCTCGTGGTGGACATCTTTGA</td>
<td>Mouse</td>
</tr>
<tr>
<td>Aqp2</td>
<td>TCACTGGGTCTTCTGGATCG</td>
<td>CGTTCCTCCAGTCTCAGTGT</td>
<td>Mouse</td>
</tr>
<tr>
<td>Ppia</td>
<td>CGTCTCCTCGAGCTGGTTT</td>
<td>CCACIONCTTGGCACTGAATC</td>
<td>Mouse</td>
</tr>
<tr>
<td>Hprt1</td>
<td>ACATTGTGGCCCTCTGTG</td>
<td>TTATGTCCCCCGTTGACTGA</td>
<td>Mouse</td>
</tr>
<tr>
<td>Sglt2</td>
<td>TTGGGCATCACCATGATTA</td>
<td>GCTCCAGGTATTTGTCGAA</td>
<td>Mouse</td>
</tr>
<tr>
<td>Trpm6</td>
<td>CACAAGCCAGTGACCACCTA</td>
<td>GAGGCTCTTGAGGGCTTTTT</td>
<td>Mouse</td>
</tr>
<tr>
<td>Snat3</td>
<td>GTTATCTTCGCCGCCCAACAT</td>
<td>TGGCCATGATCCGGAAGTAG</td>
<td>Mouse</td>
</tr>
<tr>
<td>Alpha Enac</td>
<td>CCTGGGCAGCTCCATCTTTA</td>
<td></td>
<td>Mouse</td>
</tr>
</tbody>
</table>
Reverse GACTCCAGGCATGGAAGACA
Casr Mouse 150 97
Forward CTCTGCTGCTTCTCCAGCT
Reverse GGCCTCAAATACCAGGAGGA
Cabd28 Mouse 154 101
Forward CTGACAGAGATGGCCAGGTT
Reverse AGCAAAGCATCCAGCTCATT
arl15b Zebrafish 133 104
Forward AAGGAACTCGGAGGAGCAGACTCA
Reverse AGTGGAGCTCTGTACGCGCC
elf1α Zebrafish 89 100
Forward GAGGCCAGCTCAAACATGGGC
Reverse AGGGCATCAAGAAGAGTAGTGACGC
SUPPLEMENTARY REFERENCES


**RESULTS**

16 Meta-GWAS of urinary Mg\(^{2+}\) in European cohorts (n = 9,099)

**CONCLUSION**

ARL15 is associated with urinary Mg\(^{2+}\) in the population

**Methods**

In vitro and in vivo studies of renal Mg\(^{2+}\) handling

ARL15 is a new player for renal Mg\(^{2+}\) handling that provides the first genetic link between Mg\(^{2+}\) balance and metabolism